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1. Introduction 
The European Union Drug Strategy for the period 2009–12 sets the goal to yield concrete and 
identifiable improvements concerning the knowledge of drugs trafficking. In addition, the EU 
Drugs Action Plan for 2009–12 defines among others the objectives to develop key-indicators 
of policy-relevant data on drug markets, as well as a strategy to collect them. 
In October 2010, the EMCDDA, with the support of the European Commission, developed 
concrete efforts to launch this process organising the first European conference on drug 
supply indicators. There, some additional steps were taken to define a set of technically 
sound and sustainable indicators for monitoring drug markets, crime and supply reduction for 
Europe. This event brought together a wide range of European and international experts, 
aiming to assess the current state of the art in this domain and develop a realistic strategy for 
moving forward in this area (EMCDDA and European Commission, 2010). 
This Pilot study on wholesale drug markets aims to contribute to this process, starting by 
discussing the utility of collecting wholesale drug prices in Europe. In order to assess the 
feasibility of this collection process, this study provides an overview of the procedures 
implemented nationally and of the information available in European countries on wholesale 
drug prices. Then, it suggests what information would be necessary to collect in the future, as 
well as the instrument to be used — a questionnaire. This questionnaire was tested by 
several countries which reported real data for 2008 and 2009. Finally, the data collected 
during the two rounds of actual data collection are presented. 
This study has been possible due to the contribution of the EMCDDA’s Reitox network (1) and 
national experts involved, as well to the support of Europol. This Pilot study officially started in 
November 2008 when the EMCDDA requested the Reitox network to nominate national 
experts on wholesale drug prices. A first meeting took place in May 2009. There, national 
experts discussed the feasibility and interest of developing this Project plus (2) with the 
support of Europol. Subsequently, Europol hosted a meeting where, with the help of the 
Serious Organised Crime Agency (SOCA), the first template to collect wholesale drug prices 
in Europe was drawn. This template was used to make the first round of wholesale drug price 
collection in Europe, with 2008 data. In June 2010, a second expert meeting occurred in 
London with the support of the UK National Focal Point and SOCA (3), to improve the 
questionnaire. Then, the second round of data collection was launched for 2009 data. 
During the implementation of this study, the utility and feasibility of improving the current 
systems of collecting wholesale drug prices was analysed by national and European experts. 
Benefits were compared with the required investments. In this framework, 10 countries 
revised or have set plans to revise their internal law enforcement practices, to comply with 
this data price collecting framework. In Germany, the BKA arrived to an agreement with the 
16 Federal States offices to adapt their price reporting and collecting procedures. They have 
agreed to harmonize their price categories with those defined in this Study. In France, the 
Office Central pour la Repression du Trafique des Stupéfiants (OCRTIS) has linked wholesale  
drug prices to purity. In Austria, the Criminal Intelligence Service, MOI, has improved their 
Internet-based application (which links local police stations to the central police office) with 
                                               
(1) Reitox is the European information network on drugs and drug addiction. The network is comprised of national 
focal points of the EU Member States, Norway, the candidate countries and the European Commission. Under the 
responsibility of the governments, the focal points are the national authorities providing drug information to the 
EMCDDA. 
(2) 15 countries were represented: CZ, DE, IE, IT, ES, FR, CY, LT, AT, PL, PT, SK, SE, UK and TR. 
(3) 20 countries and Europol were represented in this meeting (BE, CZ, DE, EE, ES, FR, IE, IT, CY, LT, HU, NL, AT, 
PL, PT, RO, SK, UK, HR and TR). 
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the objective of relating purity to prices. In the Czech Republic, the National Focal Point has 
made an agreement with national law enforcement to relate wholesale drug prices to purity. In 
Belgium, prices have been related to the size of the underlying transactions or seizures, 
depending on the source of the information. In Italy, Lithuania and Turkey, training is already 
planned for law enforcement agents. In Cyprus and Hungary, national law enforcement 
offices are waiting for the final Wholesale Drug Prices Questionnaire to adjust national 
procedures accordingly.  
This Pilot study is organised as follows. After a brief introduction in Section 1, Section 2 
provides a definition of wholesale drug prices. Section 3 discusses the relevancy of having 
this data to different players in the field of illicit drug policy. Section 4 describes the 
information required in order to make wholesale drug prices meaningful. Section 5 makes a 
brief presentation of data availability in Europe. Section 6 describes the questionnaires 
suggested and used to collect wholesale drug prices, as well as the results of two rounds of 
data collection, concerning 2008 and 2009. In order to provide a detailed overview of different 
national collection systems, Section 7 presents the national collection systems. Section 8 
concludes.  
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2. Defining wholesale drug prices 
 
Wholesale drug prices are prices that refer to large bulks traded with the objective of 
distributing drugs within a country, either to subsequent wholesalers or to retailers. By 
European retailers, we mean those who sell small amounts of drugs (limited number of 
doses) to final drug users in the European territory (4).  
In order to operationalise this concept, wholesale drug prices are those charged to 
transactions of approximately 1 kg or more (cannabis, cocaine, opioid products, amphetamine 
or methamphetamines). With respect to ecstasy and LSD, transactions are of approximately 
1 000 pills and 1 000 doses or more, respectively. 
These volumes were adopted for several reasons. First, because according to European 
experts (5), drug traffickers use this weight and number of pills as standard transactions 
measures for bulk transactions. Second, because national authorities and the international 
community is used to applying this definition, and to collecting and reporting prices using 
these units of account (6). Additionally, this definition also has the advantage of being 
objective and simple.  
Despite the ‘kilo’ weight being a common size of wholesale transactions, sometimes these 
transactions occur with different weights. Transactions with smaller than 1 kg volumes also 
occur, due to the wide variety of the European drug markets sizes and characteristics. There 
are countries where transactions of relatively ‘small’ volumes take place at the wholesale 
level, since their drug markets are small. Consequently, transactions of quantities smaller 
than 1 kg are still considered as being wholesale transactions. The definition of the lower limit 
of what is considered wholesale transaction is quite arbitrary, being based on experts’ 
empirical evidence. In this framework, since a cut-off point had to be decided, it was agreed 
that the lower volume considered as being wholesale would be 0.5 kg. As mentioned, this 
volume might be more adequate to apply in certain countries than others. However, this 
smaller limit was set high enough to be unlikely to integrate prices charged at the lower level 
of the market, excluding retail transactions (7). 
Accepting higher than 1 kilo transactions is also necessary, since there is not a clear upper 
limit of wholesale transactions, when compared to the next layer of drug market: the import 
market. Therefore, the agreed solution was to accept any quantity above the ‘kilo’ level, but 
distinguishing prices applied in different weight intervals (see Section 4.1).  
According to law enforcement experts, wholesale transactions are normally priced in units of 
1 kilo (or 1 000 units). The price of 1 kilo of drugs is commonly used as the unit of reference 
by traffickers to trade wholesale drug volumes, even in situations where the transaction 
volumes differ. This fact simplifies reporting, since it avoids conversion prices when different 
volumes of transactions occur. 
                                               
(4) For a detailed analysis of the retail drug market, see EMCDDA and European Commission (2010). 
(5) Based on the conclusions of the 1st  and 2nd  Expert Meetings on wholesale drug prices in Europe (EMCDDA, 19–
20 May 2009 and 28–29 June 2010).  
(6) UNODC has been publishing this information for many years in the World Drug Report. However, experts are 
unanimous in recognising the lack of effort invested in reporting reliable data.   
(7) See EMCDDA and European Commission (2010) for a discussion of the underlying difficulties inherent to the 
definition of retail drug transactions and for some suggestions on how to implement this definition. There, it is 
suggested to use maximum quantity (unadjusted for purity) thresholds under which transactions would be considered 
as retail.  
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Box 1: Is there a unique definition for wholesale drug markets and prices charged? 
As Moore at al. (2005) points out, there is no common terminology for different levels of the drug 
markets. Concerning heroin, these authors refer the existence of six market levels: cultivation (opium); 
production (heroin); trafficking (source country to distribution country); distribution (within destination 
country); street level; and consumption (final user). Then, this author calls for a careful specification of 
the ‘market’ in any analysis. 
Johnson and Golub (2006) define the role of the wholesale distributor as a major distributor in the 
destination market, called ‘kilo connection’, differentiating from importers who are in charge of smuggling 
drugs from outside the country into the domestic market. This author also distinguishes from other 
sources of traffickers that he classifies as dealers, who trade or intervene either at the regional or local 
level. 
UNODC (2007) bases its market level definition on the volume (weight) of the transacted drugs. 
Accordingly, it sets up a methodology to define wholesale transactions and equivalent prices based on 
the volume of the transaction. This definition has the advantage of being objective, easily understood 
and assessed by data providers and users. Prices are categorised according to the weight of the drugs 
which were traded. Thus, the UNODC assumes that transactions at the wholesale level involve at least 
one kilogram of cocaine, heroin, cannabis (herb, oil or resin), amphetamine or methamphetamine. 
Wholesale level transactions of ecstasy involve one thousand tablets. The main limitation of this 
analysis remains the quality of the data supplied to the UNODC. This institution bases its information on 
its Annual Report Questionnaire. Sometimes, the UNODC does not receive data referring to the pre-
defined amounts, which obliges them to estimate prices after converting the amounts reported into those 
pre-defined. This operation may introduce an element of error to wholesale prices. As Caulkins and 
Padman (1993) extensively demonstrated, drug prices react strongly to changes in the size of the 
transactions. As a result, conversions may lead to erroneous calculations 
Caulkins at al. (2009) describe drug transactions based on interviews of convicted drug law violators. 
They argue that the wholesale drug market links import markets to local retail markets and that the 
wholesale drug market is characterised by the existence of transaction cycles. These transactions 
cycles show important similarities across the different drugs traded. 
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3. ‘Need to know approach’: Why collect wholesale drug 
prices? 
 
The collection and monitoring of wholesale drug prices will contribute to supporting the work 
of those who implement supply reduction policies. Since the close monitoring of these prices 
facilitates a better understanding of the main goal of drug traffickers, i.e. of drug profits, its 
monitoring enables the improvement of current strategies to combat illegal trafficking. Box 2 
describes some features of wholesale drug markets and prices. 
There are different actors involved in supply reduction and in the monitoring of drug markets: 
law enforcement and judicial staff, policy makers and researchers. A better monitoring of 
these prices will contribute to support their activities in different ways. Sub-sections 3.1, 3.2, 
and 3.3. discuss the utility of monitoring wholesale drug prices. Sub-section 3.4 extends this 
analysis to purity-adjusted wholesale drug prices.  
 
Box 2: The functioning of the wholesale drug market: paying for the service of distributing 
drugs? 
As in any other market, licit or illicit, wholesale prices reflect the interaction between supply and demand 
at the wholesale or bulk level, with the aim of distributing goods to other intermediate traders, lower in 
the distribution chain, or to retailers. This is still the case when it concerns drugs. In Europe, the supply 
of wholesale drug markets can have either an imported origin (for instance, in the case of cocaine or 
heroin produced in the Andean region or in South Asia, respectively) or they are produced domestically 
(in the case of methamphetamines or cannabis). In wholesale drug markets demand can come either 
from another level of the wholesale distribution within the consumer country (e.g. when regional 
wholesalers sell to local ones), or from retailers. 
At the wholesale drug supply level, the elements that influence the prices charged are several: 
1. The cost of the drugs traded — the price that the wholesaler has paid either to the importer, the 
previous wholesaler or the domestic producer will impact the prices charged by wholesalers. 
When drugs are imported, besides the price of drugs itself, the currency used to set this 
transaction has also an impact on the cost of drugs (for example, if drugs are sold in dollars to 
European wholesalers, a decrease in the price of the dollar decreases the cost to the 
wholesaler who pays in euros). When drugs are produced domestically and the wholesaler is 
also a producer, he will have to take into account his producing costs (for instance, in the case 
of cannabis in-house production: seeds, land, electricity bills, etc.); 
2. The costs of distributing — these costs range from expenditures in personnel (if he employs 
lower level traffickers), to technological devices (e.g. specially adapted vehicles that allow drug 
transportation without being detected or high technology telecommunication tools); 
transportation (vehicles and petrol used, for instance), packaging, etc; 
3. Stocking — in case the distribution process requires that merchandise is kept in stocks for 
certain periods of time, then the costs associated with the storage and hiding of drugs can be 
relevant; 
4. Risk — in order to account for the illegal activity of trafficking drugs, individuals require a 
certain remuneration that compensates for the risk of either going to jail or of being subjected 
to violence (since there is no legal way of guaranteeing the respect of buyers/sellers rights). In 
addition, part of the merchandise can be seized and they may lose part of the payments due, 
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with no legal methods to guarantee transactions; 
5. Purity/potency — the mixing/dilution of drugs with cutting agents (normally traded in the legal 
sector) despite reducing the quality of the drugs provided, increases the volume of drugs sold, 
at a small cost. Since the change in final quality of drugs is not easily perceived by the next 
buyer in the purchasing chain, reducing purity is a method used to reduce costs in the 
wholesale drug business. At the wholesale level, this incentive to reduce the cost of the drugs, 
might be somewhat compensated by the potential increase in the risk of trafficking. When 
drugs are adulterated, the volume of the illegal merchandise increases. Consequently, cutting 
might lead to a rise of the probability that these drugs become easily detectable by law 
enforcement; 
6. Branding — some drug dealers try to assign brands to their drugs in order to differentiate them 
and to associate this drugs with a certain purity/potency or special qualities of these drugs in 
order to charge higher prices. This happens frequently with ecstasy pills (where logos and 
colours are assigned to drugs) and in the packaging of cocaine bricks at wholesale level; 
7. Profit — the net revenue that high-level traffickers gain from their activity of distributing drugs 
on the market is crucial to determine drug prices. The total profit is the profit gained on each 
kilo of drugs sold (profit margin) multiplied by the total volume of drugs sold. Besides the six 
elements previously considered, profits also depend on the structure of drug markets. The 
higher the number of sellers competing to sell drugs in the market, the lower the prices 
charged. 
Where drug demand is concerned, the main components that will determine the maximum price retailers 
are willing to pay for the drugs they buy with the intention of selling it afterwards to drug users, are the 
same as for the wholesaler, i.e., the expected profits of trafficking these drugs to the next level of the 
market. The main differences compared to previously enumerated factors are the smaller volumes 
traded and the proximity with the final drug user. 
All in all, wholesale prices will result from the interaction between demand and supply. In situations 
where there is a large volume of drugs supplied to the market, as compared to demand, the ‘equilibrium 
price’ tends to decline. The opposite happens when demand of a drug is much bigger than its supply. 
Additionally, the structure of the market is also relevant. Normally, when the number of wholesalers 
increases, there is more competition within sellers, so price tends to decline. The opposite tends to 
happen when there is an increase in the number of buyers. 
 
3.1. Need to know: law enforcement and judiciary perspective 
(Pascal Garllement,Tony Saggers, Cláudia Costa Storti) 
 
A more effective fight against drug traffickers requires a good understanding of their business, 
since profit is one of their main driving forces. Policy-makers and law enforcement officials will 
be more effective when traffickers’ business plans are well understood.  
Since crime is global, i.e. it is not limited or severely constrained by national borders, the 
understanding of national crime networks and markets becomes more and more insufficient. 
This is especially true in Europe, where full mobility of people, goods or capital is almost 
complete across European countries. Elements such as international agreements settled by 
EU countries; technological developments — allowing decreases in the cost of international 
communications and transportation; or high volumes of international trade; and financial 
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integration have reinforced the need to draw a clear and wide picture of worldwide drug 
trafficking. 
A good knowledge of wholesale drug prices and an effective sharing of this information within 
European partners contribute to this task. There are several reasons for this: 
• Wholesale drug prices (WDP) are a key variable to drug dealers, since they 
determine their revenues and profits and, therefore, sustain their business (See Box 2 
for further insights). It is important to note that wholesale drug prices will influence the 
profits of both the drug importers — since they sell drugs to wholesalers — and to 
drug retailers. The higher the price paid by drug retailers to the wholesaler, the 
smaller the retailer’s profit (considering that the purity level remains unchanged) or 
the higher the price retailers charge to drug users. Knowledge of WDP will allow a 
good understanding of local drug markets; 
• Wholesale drug price awareness facilitates opportunities to interpret markets, 
understanding new market trends, and expose elements of industry, logistics and 
associated criminality; 
• Wholesale drug prices are less influenced than seizures by small changes in 
trafficking routes, so they give a better indication of the level of total drugs available in 
a country. Furthermore, the geographical spread of offences and seizures, may more 
easily reflect forces’ investment in data capture rather than the actual depth of the 
problem in an area; 
• Organised crime and drug trafficking operates on national and international levels. 
Consequently, the sharing of wholesale drug prices in Europe enables a better 
understanding of domestic trafficking and to detect new international trafficking 
trends. All importation investigations will, by the very nature of the enterprise, involve 
trafficking activity and commodities within multiple countries and trading 
environments. Consequently, a full picture is only provided when assessing and 
comparing national wholesale prices with a wider arena; 
• In operational terms, the collection of WDP allows law enforcement to build 
awareness of the ‘most commonly encountered’ prices which, when monitored over 
time, may provide valuable information concerning market trend changes and, 
eventually, alert mechanisms. 
Can wholesale prices be used to reflect law enforcement activity? On the one hand, 
wholesale drug prices also indicate law enforcement activity, as a consequence of changes in 
risk depending on the intensity and effectiveness of law enforcement activity (see Box 2, for 
further information), and are sometimes used as indicators of policing activity (8). When police 
forces invest more in combating high-level drug trafficking (e.g. devoting more staff and 
money to arrest important traffickers and make large seizures), this makes trafficking more 
expensive (replacement of either lower level traffickers or seized drugs). In this case, more 
and better law enforcement leads to higher wholesale drug prices. On the other hand, these 
prices are influenced by factors other than law enforcement activity. For instance, in case 
there is a sudden decrease in drug production due to bad weather, prices of imported drugs 
may rise sharply, with an impact on domestic wholesale drug prices. In this case using WDP 
to assess law enforcement activity is misleading. This is also the case when prices vary due 
to changes in drug demand. Thus, wholesale drug prices can also change due to reasons 
which are not explained by policing activity. All in all, it must be concluded that prices should 
be carefully used when the intention is to measure law enforcement activity. 
                                               
(8) See Bright, D. and Alison, A. (2010), for a deeper discussion of this topic. 
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Being more specific, the periodic sharing of WDP at European level contributes for local law 
enforcement activity because it allows: 
• Better management of scarce resources: a deep knowledge of on what level of the 
trafficking chain profits are higher, allows for a better management of law 
enforcement scarce resources, since law enforcement activity can be focused at the 
core of the criminal action;  
• Intelligence interpretation: intelligence takes many forms but often demands elements 
of interpretation as the information is not always specific and transparent. With 
particular regard to covertly monitored conversations, criminals rarely use explicit 
vocabulary with regard to intentions or commodities. Awareness of national and 
international WDP greatly increases capabilities to understand this form of 
intelligence with obvious implications upon the allocation of resources and successful 
targeting of criminals; 
• Briefing covert deployments: the safe and resilient deployment of undercover officers 
demands credible and often detailed awareness of criminal markets, including WDP. 
Many such investigations entail international influences and a demand for wider 
knowledge. Highly informed briefings and operative insight are linked directly to risk 
management and ultimately to successful operations;  
• Evidence and expert evidence: at the conclusion of an operation, it is often highly 
beneficial to identify evidence that can be presented or interpreted to demonstrate 
criminal conspiracy or conduct. Covertly recorded conversations, written notes or 
calculations by those arrested will often implicate drug commodity and price 
awareness. It is possible to introduce such evidence if links can be drawn to prices 
applied at the time of the events in locations where these events occurred. If law 
enforcement collects and monitor prices, this will likely afford greater evidential value, 
enhancing the impact of the case; 
• Proceeds of crime: the value of a drug consignment can often be estimated when 
calculating profits achieved and illicit income generated over a period of time from 
drug trafficking. As many of these cases involve wholesale quantities, it is essential to 
apply credible and up-to-date WDP to each consignment or string of events. If drugs 
are being traded across international boundaries, values in other countries may also 
be applied to such cases;  
• Assets confiscation:  A criminal file needs information about WDP in order to obtain 
accurate and credible estimates of illegal profits. Only then will it be possible to 
estimate the value of the equivalent asset that should be confiscated; 
• Market trends: New and emerging trends can be identified through monitoring WDP. 
Trends may be influenced by the economic environment, law enforcement impact, 
policy and law and criminal innovation or seeking out new opportunities. If law 
enforcement collects and assesses drug prices throughout the year, the emergence 
of new high or low prices either at regional or national level may indicate changing 
trends, trafficking methods or regions/countries within which they are acquired. This 
cannot be achieved as efficiently if conducted periodically;  
• Impact assessments: It is fair to acknowledge that law enforcement activity can 
impact upon the price of certain commodities within given periods. While this is not 
always easy to measure; it is far more achievable if prices are being collected and 
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monitored as changes or reactions to specific priorities or targeting can be assessed. 
While price is not necessarily the only indicator, it can, however, be analysed and 
compared to other factors, such as purity (or quality) for powder drugs or availability. 
It is important noticing that interventions with influence on the wholesale market are 
going to have an impact also at retail and import level. 
• Formal reporting: All countries have formal demands to report drug prices. By 
creating a central and credible framework within which WDP are collected, monitored 
and reported will generate corporate returns and externalities. As drug trafficking is a 
European/international problem it can only be solved through European/international 
cooperation. European and international wholesale drug price monitoring is one of the 
tools available to law enforcement but must be maintained within a credible 
framework to be successful. Collecting data at the EMCDDA is an effective way of 
sharing information at European level, since this Centre is specifically devoted to the 
task of managing, sharing and monitoring data at European level. 
3.2. Need to know: policymakers’ perspective 
 
At international level  
At the 52nd meeting of the Commission on Narcotic Drugs (CND) for UNODC on March 2009, 
the latest international gathering of drug policy-makers, it became clear that an international 
focus would improve the quality of data collection in the drug field. Out of this meeting, a 
political declaration was issued with the following text (9): ‘[…] Member States took account of 
the need for indicators and instruments for the collection and analysis of accurate, reliable 
and comparable data on all relevant aspects of the world drug problem and, where 
appropriate, the enhancement or development of new indicators and instruments.’ 
Consequently, the CND requests a revision of the data collection tools, as well as additional 
funds to member countries. 
At European level 
In the EU Drug Strategy, it is concluded that continued progress should be made concerning 
the availability, quality and comparability of information on monitoring the drug situation. 
Furthermore, in the field of supply reduction, the document sets the objective of yielding 
concrete, identifiable and measurable improvements by 2012 concerning the effectiveness, 
efficiency and knowledge base of law enforcement interventions and actions, targeting 
production and trafficking of drugs, among others. This strategy also recognises that in order 
to implement this priority, it is necessary that policy makers and law enforcement agencies — 
both EU and national — improve and share their knowledge. 
Furthermore, the EU Drugs Action Plan for 2009–12 sets the objectives of developing 
European indicators to collect policy-relevant data about, among others, drug markets, as well 
as to develop a strategy to collect them. The EMCDDA and Europol are referred to as being 
in charge of this task. 
This project contributes to attain this objective in different ways. First, it enhances the sharing 
of operational information that can have a positive impact on law enforcement activity. 
Second, together with other variables, WDP may constitute an instrument to evaluate the 
effectiveness of law enforcement intervention either at local, regional or aggregated level.  
 
                                               
(9) See UNODC 2009, CND Resolution 52/12.  
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At national level 
This concern has been reflected in the national strategies in different ways, especially in 
those written after the EU Action Plan for 2005–12. Until January 2010, there have been at 
least two national policy documents approved in European countries, with special reference to 
this area. 
One is the Spanish National Drugs Strategy 2009–12 (10). This document follows the EU Drug 
Strategy guidelines. It sets as one of the top priorities for the supply reduction strategy the 
need to increase the effectiveness, efficiency and knowledge base of law enforcement 
interventions and actions, targeting production and trafficking of drugs. Then, it goes further in 
detail, setting the priority that the Spanish law enforcement bodies should fight drug organized 
crime, especially in the following four stages of the process: first, at drug production; second, 
during its distribution at the wholesale level (where international trafficking and domestic 
trafficking are explicitly considered); third, at the retail level, and; finally, during money 
laundering. Furthermore, it sets as a core priority the need to build on the current intelligence 
capacity to analyse the drug phenomena, anticipating new trends and reacting to new drug 
trafficking and money laundering developments.  
The other one is the Portuguese Action Plan for the period 2009–12. There, it is set as a 
priority to increase the Portuguese capacity to collect information on drug supply and drug-
related criminal activity, as a tool to enhance the Portuguese supply reduction policy. 
Additionally, the need to implement research that helps explaining drug supply and markets is 
also identified.  
It is thus clear in both documents that the analysis of markets is a top priority for these 
countries. In the Spanish case, the wholesale drug market is viewed as an important market 
to monitor, while in the Portuguese case the emphasis is given to the need of building on 
existing information, namely developing the dataset currently available to monitor supply and 
supply reduction activity. In both cases, collecting wholesale drug prices can give a useful 
contribution to the implementation of the recent European national drug policies. 
3.3. ‘Need to know approach’: the research community 
One of the main challenges faced by researchers in the drug field is the scarcity of data. This 
problem is particularly relevant where drug supply is concerned. When compared to other 
regions of the developed world such as the US and Australia, the European picture becomes 
even gloomier. There are several contributing factors to explain this. Nevertheless, its 
consequences are that scientific knowledge in this area is still craving for a sufficient volume 
of data that allows evidence-based analysis.  
A full understanding of the relationship between wholesale drug prices, retail prices and the 
availability of drugs is necessary to understand how supply reduction policies can become 
disruptive, making drugs less available to final drug users.  
Wholesale prices and purity adjusted wholesale prices are a further step in a long journey. 
The utility of this database increases when it complements others existing and more 
developed data bases. This is the case for the European retail prices database or the large 
volumes seizures databases. This is also the case when researchers and policy makers try to 
apply harm reduction considerations to drugs supply policies, as it has been the case in the 
UK and Australia.  
                                               
(10) See Bolletin Ofiicial del Estado, N 38, Sec I, Pag. 15284, 13/02/09.  
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4. Enhancing the utility of collecting wholesale drug prices 
The interest and reliability of the wholesale drug prices collected is enhanced when 
complementary information is also monitored. Therefore, this section discusses the utility of 
monitoring and sharing information on wholesale quantity discounts, on the methods used to 
collect prices, on drugs purity and on regional price differences at European level. The 
statistical methods used will also be reported briefly. 
4.1. Quantity discounts  
The further one moves down in the distribution chain — from the source to the consumer — 
the higher prices become. The same is true for illicit drug markets (Caulkins and Padman, 
1993 or Caulkins at al., 2009). As in legal markets, the price charged per kilo increases when 
the total volume traded declines. Drug prices tend to increase when the volume of the 
underlying transaction declines.  
In real life, wholesale drug transactions occur within a wide range of traded volumes. 
Consequently, in order to have meaningful information about prices in the wholesale markets, 
where the weight of the transaction may vary from 1 kilo to 1 tonne, it is important to have 
prices reported according to volumes traded. 
As mentioned in Chapter II, trading volumes of approximately 1 kg are considered as the 
common threshold of wholesale transactions. Based on the empirical evidence reported by 
national experts, it is difficult to clearly define a maximum threshold towards the next upper 
level of the drug market, i.e. the import market. Therefore, it was decided to consider as 
wholesale drug prices every price charged in transactions close to and above 1 kilo, occurring 
within the European territory. This characteristic entails important consequences to the price 
collection system, namely, that the system receives price information of very different 
volumes traded. 
In order to operationalise this market ‘empirical rule’, capturing the impact of quantity 
discounts on wholesale drug prices, it is desirable to associate the wholesale drug prices 
reported by the weight of their underlying transaction. In this case, it is avoided to arrive to 
unrepresentative mean prices, charged to transactions varying between 1 kg and more than 1 
tonne.  
The price of individual transactions is not relevant at the European level, since it would be too 
much data. Instead, it is useful to have information on prices associated with weight ranges. 
Four main weights ranges were defined, as agreed with national experts, according to their 
empirical experience. The defined weight ranges intend to accommodate the characteristics 
of different national European drug markets. These weight ranges are: 0.5 kg–1.5 kg (500 to 
1 000 pills), between 1.5 kg and 10 kg (1 000 to 10 000 pills or units), between 10 kg and 100 
kg (10 000 and 100 000 units) and, finally, weights above 100 kg (100 000 units).  
However, empirical experience shows that there are still countries which are not ready to 
report with this level of disaggregation and detail. Consequently, taking this into account, the 
possibility of reporting undifferentiated wholesale prices in a separate column is still foreseen 
(if assured that prices correspond to transactions with volumes close or above 1 kg).  
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Box 3: A case study — Germany: different wholesale volumes, different prices 
(Heiko Hergenhahn and Cláudia Costa Storti) 
Germany has collected wholesale prices of the main drugs trafficked in the country for many years. The 
length of data series differs according to drug and to the segment of the wholesale market. Transactions 
with volumes close to 1 kg have been collected for long periods: cannabis resin and heroin prices have 
been collected since 1975. The collection of prices of larger transactions (above 10 kg) is more recent, 
having started for most drugs in 2000. In this case, since the number of very large transactions is 
naturally smaller, information is scarcer and price series fluctuate more over the years. Figure 1 shows 
the available data (11). 
Figure 1: German wholesale drug prices: different volumes, different prices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: BKA, 2010. 
German wholesale drug prices show: 
• when analysing WDP, we conclude that prices applied in smaller wholesale transactions (of 
volumes between 1 and 10 kg) are consistently higher than those charged in larger 
transactions (volumes superior to 10 kg), when the same drug and year are considered. So, it 
is clear that quantity discounts are applied in the German wholesale drug markets; 
• wholesale drug prices of different drugs show clear trends over time; 
• concerning cannabis wholesale drug prices, data show that resin and herb prices had different 
patterns. While herbal cannabis prices revealed a clear upward trend, resin prices show signs 
of relative stability. Furthermore, while wholesale cannabis herb intermediation margin (the 
difference between the price of big volume and small volumes) declined significantly, the same 
is not observed in the resin market; 
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• heroin wholesale prices show continuous declines after 1985. It is interesting to notice that 
intermediation margins are also among the smallest observed, when compared to other drugs, 
over the same period; 
• in the cocaine market, after 1985, the decline observed in the prices of small volumes was 
followed by a fall in the prices of large volumes; revealing that the intermediation margin has 
remained relatively constant in Germany; 
• ecstasy wholesale prices have also declined, in both large and smaller volumes. However, 
intermediation margins have been increasing slowly but firmly in this market. 
 
4.2. Collecting purity adjusted prices 
(Klaus Stempel, Pascal Garlement, Tony Saggers, Cláudia Costa Storti) 
As mentioned in Box 2, reducing the purity/potency of traded drugs is a way of reducing 
wholesale drug costs and, therefore, of increasing traffickers’ profits. Consequently, all drugs 
are vulnerable to and inevitably subject to adulteration. It is common that the bigger volumes 
traded, the higher their purity or potency, since adulteration occurs within the distribution 
chain. In order to reduce the costs of transportation and the probability of being seized, there 
is an incentive to do bulky wholesale transactions with a high degree of purity, reducing the 
volume of the shipment. However, along the distribution process, the volume of the shipment 
becomes smaller. Therefore, the risk declines of having a large volume of drugs detected and 
seized. Consequently, it becomes more attractive to cut drugs, which decreases its cost and, 
if sold at the uncut price, increases its profitability. Since drugs sold in smaller portions usually 
pass through many transaction cycles of the supply chain, they are traditionally adulterated.  
It should be stressed that wholesalers rarely know the exact purity level of drugs they sell (12). 
However, they are usually aware of its approximate or perceived quality. With respect to drug 
retailers, the purity of drugs is usually even less known. So, prices reflect not the exact level 
of purity sold, but an approximate value that, on the one hand, sellers think they have to sell 
and, on the other hand, buyers perceive to be buying.   
In this framework, purity is an element to take into account when drug prices are analysed, for 
the following reasons: 
o Reflects the real value for money of drugs traded. Since there is some nominal 
price stickiness in markets, i.e. retailers do not like to pay different prices for the 
same purchased good, and since there is no accurate information about the 
purity of drugs that are being bought, an ‘easy’ way of increasing the price 
received for the selling of the same weight of pure drugs is decreasing supplied 
purity (13).  
o Informs about the volume of revenues and profits gained by traffickers in drug 
transactions, with the consequences discussed in Box 2. 
o Allows for more accurate regional and international comparisons of drugs prices. 
Comparing drug prices in different locations might became erroneous if purity is 
not taken into account. Indeed, the same price may reflect a very different actual 
volume of the drugs traded, when different cutting levels are applied to the same 
drug. 
o Higher purity may indicate proximity to trafficking routes and/or higher levels of 
the wholesale drug markets. Big bulks of trafficked drugs are a factor that can 
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contribute to higher probability of being detected by law enforcement. 
Consequently, the wholesaler traffickers have incentives to keep drugs pure. 
However, when the level of the market approaches the final users, this risk is 
counterweighted by the increase of profit due to selling drugs which are less pure. 
So, the purity-adjusted price can be used as an indicator of proximity to the 
trafficking source.  
o Allows for more accurate comparisons of drug prices over time. Comparing drug 
prices in different periods of time became erroneous if purity is not taken into 
account. Indeed, the same price may reflect a very different actual volume of 
drugs traded, when different levels of cutting exist. 
o It contributes to a more effective law enforcement intervention. The knowledge of 
the purity-adjusted prices practiced in the different local and regional markets is 
essential to guarantee law enforcement effectiveness and security when 
developing under-cover operations. The same is true for the intelligence 
interpretation, analysis of new trends, evidence and expert evidence, proceeds of 
crime and assets confiscations. Impact assessment is also only accurate when 
purity issues are taken into account.  
o Compared to other frequently used market indicators, such as seizures and 
number of arrestees, wholesale prices are less dependent on the level of efforts 
taken by law enforcement staff. Consequently, they are a better measure of drug 
markets activity than these other more traditional alternatives.  
 
Box 4: Purity-adjusted prices: The UK example over the last decade 
In the UK, the evolution of cocaine prices shows the importance of analysing prices and purity in 
parallel, in order to fully understand cocaine markets. Over the last 10 years, the price of the ‘cocktail 
containing cocaine’ sold in the UK (within a gram deal) has fallen consistently. From about GBP 65 per 
gram, in 2000, it declined to about GBP 35 per gram, in 2009. Conversely, the price of a compressed 
kilogram of cocaine rose steadily from about GBP 20 000 to GBP 52 000 (with examples of over GBP 
60 000) over the same period. These two examples, when considered without taking purity into account, 
generate obvious conflict and suggest profit has become much smaller recently across the UK market 
supply chain. 
However, the monitoring of purity levels throughout these domestic markets show that significant profits 
have been achieved, by adulterating cocaine at various stages of the supply chain. Indeed, in 2009, it 
was common that one wholesale kilo of cocaine would originate over 6 kg at retail, by bulking it with 
pharmaceutical and commercial powders. The purity-adjusted trends have evolved as follows: 
• Over the 2000–05 period, the common purity of street level cocaine varied between 40 % and 
50 %; 
• Over the 2005–08 period, common street level purity fell to a range between 30 % and 40 %; 
• From late 2008 to the end of 2009, street level purity fell dramatically to a range between 10 % 
and 20 %, with frequent examples below 10 % towards the end of 2009; 
• Over the complete period 2000–09, the common purity of wholesale kilogram blocks of cocaine 
ranged consistently between 65 % and 70 %, within a wider range of 60 % to 80 %. 
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Table 1 
 Retail level Wholesale level 
Cocaine 2000 2005 2008 2009 2009-2000 
growth 
2000 2005 2008 2009 2009-2000 
growth 
Price per gram 
(₤) 
65 50 40 35 -46 % 20 28 38 52 160 % 
Purity 50 40 28 10 -80 % 70 65 63 65 -7 % 
Purity-adjusted 
price 
130 125 143 350 169 % 29 43 60 80 180 % 
Source: SOCA 2010 data. 
Please note that the figures engaged in the above calculations are accurate and representative of findings at the 
time, sufficient to demonstrate the principles regarding wholesale price and purity, but should not be taken as totally 
encompassing of all data available within any given period. 
These figures allow drawing a clear trend when comparing price and purity. Despite the quality of 
cocaine at wholesale remaining very much the same over the last 10 years, its wholesale price has 
consistently increased. Consequently, the traffickers’ value of a kilogram has increased by 180 %. At the 
retail level, traffickers’ cocaine value has also steadily increased (169 %): despite the quality of cocaine 
at street level has decreased by approximately 80 %, while prices have less than halved. 
We conclude then that the price of pure cocaine at the wholesale level has consistently increased in the 
UK over 2000–09. Simultaneously, while the price of ‘the cocktail of powder marketed as cocaine’ at 
street level has fallen, its cocaine content has dropped even further. Therefore, the retail price paid for 
pure cocaine over this period increased markedly. This market trend information contradicts the ‘simple’ 
picture provided by the analysis of price data alone (without considering purity). 
This example shows that the simple analysis of drug prices may hide contrasting underlying trends 
when adjusting for purity. Judging law enforcement activity based on prices without taking purity into 
account may lead to erroneous conclusions. 
 
4.3. Methods used to collect wholesale drug prices 
(Tony Saggers) 
The methods used to collect price data are an important issue since they determine the 
quality of databases. In the case of illegal wholesale prices, collection methods became even 
more relevant. Collection of illegal data, especially concerning huge transactions (where the 
financial amounts involved are big), requires very specific and sometimes onerous 
techniques. These techniques are frequently under the responsibility of law enforcement 
forces (being possible that other actors may play this role), whose motivation to collect data is 
sometimes limited. This section describes the most frequently used techniques and discusses 
their advantages, from the perspective of price data monitoring. 
Arrestees 
Many persons arrested for criminal offences have involvement with trafficking. Their detention 
facilitates an opportunity to discuss WDP at the time of formal interview (if their detention is 
drug-related) or on a more casual basis if their knowledge of WDP later becomes apparent. 
One of the dangers of seeking such knowledge at a time when an individual is under 
investigation for drug trafficking is that they may provide data which supports an element of 
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their defence, being potentially more motivated towards self-preservation. Consequently, 
there is a strong probability of underestimating WDP prices revealed. 
Convicted prisoners 
Visiting convicted prisoners to debrief them regarding WDP provides an opportunity for 
seeking knowledge from those proven to be directly involved in the wholesale drugs industry. 
While there may be personal motivations for the prisoner to interact, it is less likely that the 
information they provide will have a direct impact upon their own situation. Consequently, 
despite there being sometimes the problem of short memory, so prisoners may not accurately 
remember prices applied, there is less incentive to underestimate prices charged. Sometimes, 
detainees may overestimate their importance in drug trafficking, increasing drug prices if they 
perceive that the value of their trafficking may ‘increase the respect’ of the interviewer (Matrix 
Knowledge Group, 2007). The collection of such data can be tested against other similar and 
existing insight and often directly correlated with the level of activity the prisoner was known 
to be engaged in or around. 
Informants  
The use of paid or rewarded individuals providing information to law enforcement (LE) is well 
established. These persons are often very well associated with criminal enterprises and may 
have maintained personal involvement over a prolonged period of time. Although the primary 
focus for LE is very often the recovery of intelligence leading to successful operations, such 
contacts offer excellent opportunities to monitor thematic changes within the dynamics of the 
drugs industry. As this system commonly operates upon a reward-based platform, and 
although misinformation does occur, individuals are likely to be motivated towards good-
quality information.  
Covert purchases 
LE officers are routinely deployed into undercover environments where they become involved 
in the negotiation and often agreed purchase of wholesale quantities of drugs. Over a period 
of time, their insight of changing WDP becomes highly insightful as this will often be 
accompanied by perspectives of what has influenced certain prices, why, where and when. 
Like informants, undercover officers (UCO) gain insight of WDP within national and 
international markets but also provide reassurance of the integrity of the information. UCO 
can, of course, also be misinformed by criminals who they encounter. Misinformation is 
common within organised crime but through this methodology, the UCO can also provide 
degrees of certainty as to the genuine nature of their encounter. 
Interception of conversations (intelligence or evidential) 
Although misinformation exists and criminal conversations are often coded or less than 
explicit, it is possible for LE staff with experience in this field to extract detail which, when 
interpreted or placed into context can be highly insightful concerning WDP within national and 
international arenas. Care must be taken to assess such data within the wider perspective of 
the scenario to ensure the correct price, currency and commodity is being reported. It is 
common for traffickers to remove zeros from the figure being discussed and it is therefore 
also necessary to understand the quantity of drug being discussed to accurately interpret the 
monetary value per unit.  
Evidence recovered (written notes, calculations and ledgers)  
Drug trafficking is a cash rich industry with many variations of payment. For this reason, 
traffickers will often maintain records in open or coded formats. They also maintain stock 
control and conduct calculations regarding outlay, logistical costs, transport, overheads and 
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profit margins. The recovery and interpretation of such documents can be highly informative 
regarding WDP and influences upon these prices. Achieving such interpretation often requires 
assessment from a specialist. 
Collateral operational intelligence 
Throughout any operation, there is the potential for information and intelligence to emerge 
that is neither sought after nor relevant to the particular investigation. WDP have the potential 
to emerge within various other organised crime investigations and if prioritised, as an issue of 
LE importance can be captured and contributed into the necessary reporting mechanism.  
Expert assessments 
Experts with knowledge of WDP and the markets within which they are applied exist within 
various establishments, agencies and LE. These individuals have the potential to take 
information and data which does not necessarily explicitly reflect a specific commodity price 
but by applying perspective, insight and context can demonstrate how this particular data 
reflects WDP or can be used to generate an indication of what they are likely to be for a 
certain commodity or market place.  
International cooperation and insight 
Many of the examples above have the potential to entail international cooperation with partner 
agencies and opportunity for one country to achieve insight into WDP within several others as 
an operation or intelligence commitment develops. Collating and sharing this insight in an 
appropriate and timely manner can afford significant international benefits. Drug prices vary 
from country to country and are influenced by many factors including location and discount for 
bulk purchase. International cooperation through law enforcement, academic or other 
establishments will inevitably generate a sound platform upon which prices can be monitored 
and understood. 
Academic and social surveys   
Many surveys are facilitated by departments for health, welfare, counselling agencies, 
academics and independent bodies. Although these tend to commonly focus upon street or 
retail drug prices (as the demographic for such surveys is far greater) they may occasionally 
retrieve information and data concerning WDP. While such surveys are often anonymous 
(and therefore have no implication to the contributor), they can also be difficult to assess for 
credibility unless conducted with a wide reaching approach and with data requirements that 
can be applied and assessed to ongoing thematic information. Few WDP are currently 
generated from such surveys. 
Open source and research material 
Open source reporting is commonly initiated by academic research, national surveys or 
sanitised LE data edited to protect sensitive aspects of knowledge or methodologies. The 
content of open source material may often have been generated by contributions from many 
of the more sensitive methods detailed above; having been sifted and collated within a 
greater sphere of knowledge and data. Publications from national focal points, the EMCDDA 
and United Nations regularly contain sanitised data which has been subjected to professional 
review and analysis prior to inclusion. The Internet, research papers, non-fiction books and 
documentaries all offer varying opportunities to acquire knowledge of WDP. E-forums are a 
particular source of market information with participants freely sharing experiences and views 
of their own encounters.  
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4.4. Methods used to relate wholesale drug prices with purity 
In order to arrive at prices adjusted for purity, there is the need to integrate two types of data. 
The first is obviously the wholesale drug prices data, while the second is the data on purity of 
traded drugs at the wholesale level. While most of the time the main source of wholesale drug 
prices is law enforcement, this may not always be the case where purity/potency is 
concerned. This fact raises specific issues. In this section, we will list some of the issues that 
need to be tackled, to link these two datasets: 
 While in the case of wholesale drug prices, the purity at different market levels may 
be collected through methods which do not require the seizure of drugs, in the case of 
purity this always has to be the case; 
 In some countries the information on purity/potency is only requested for a small 
sample of the drugs seized. The criteria to determine the number and characteristics 
of samples that are analysed vary from country to country; 
 In some countries, the purity/potency analysis is made in institutions other than those 
where the seizures were made. Additionally, there are countries where there is only 
one public institution in charge of purity analysis, while in some other countries this 
service is decentralised and operated both by public and private entities. 
Consequently, it may happen that the results of the forensic institutions are not resent 
to the price data collectors and/or that the articulation between these two types of 
data collectors in not fully integrated. 
 In the case where information on purity is re-sent to the price data collectors, it is not 
always the case that purity samples are fully identified, so it is not possible to 
establish a clear link between the price of the drug transaction (and its weight) and its 
purity. 
Currently, there is a great diversity of situations in Europe. It seems that each country 
presents a unique situation. The data that we will present on purity related to wholesale prices 
is based on national expertise. Further effort still should be done to better analyse the 
available information and collecting situation in European countries. Box 5 presents the 
German practice, as an example of integration of wholesale drug prices and purity/potency 
data. 
Box 5: Collecting wholesale drug prices and their purity in Germany 
(Klaus Stempel) 
This box describes the basis of the procedures followed in Germany concerning the collection of data on 
wholesale drug prices and purity. It intends to show how the results of forensic analyses, carried out to 
determine the active ingredient content of narcotic drugs seized by the authorities, are used as an 
indicator for the development of the drug market and how a comparative examination with wholesale 
drug prices can be conducted. 
Between 50 000 and 60 000 seizures of narcotic drugs are carried out in Germany each year. Not all of 
the seized drugs are forensically examined to determine their active ingredient content. The active 
ingredient content is only determined in cases where it is not clear whether the quantity seized is to be 
classified as a so-called ‘non-negligible quantity’, because this classification serves as the basis for the 
indictment and the assessment of punishment by the court. In some other cases, the active ingredient 
content of seized drugs is determined, by order, by the public prosecutor's office. Information on the 
active ingredient contents and cutting agents of the most important drugs, which are detected by the 
forensic laboratories of the state criminal police offices, the Federal Criminal Police Office and the 
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Federal Financial Directorates, is forwarded to the Federal Criminal Police Office and analysed on a 
yearly basis. The central analysis of active ingredient contents is based on approximately 20 000 
individual results of forensic examinations carried out by German laboratories each year. 
For heroin, cocaine, amphetamine and amphetamine derivates, the median active ingredient contents 
are calculated. With regards to cannabis, the active ingredient contents of herbal cannabis, cannabis 
resin and cannabis concentrate are recorded and analysed separately. Since the purity of heroin and 
cocaine preparations depends on the quantities seized, their active ingredient contents are broken down 
into three weight categories. One category comprises samples weighing up to one gram, which 
represents the lowest trade level, the so-called ‘street-level trafficking’. The second category contains 
preparations with a weight of more than one and up to 1 000 grams. The third category is comprised of 
samples with a weight of more than 1 000 grams. 
The active ingredients are usually contained in the drug preparations in the form of either base or salt. 
For the better comparability of the results, the contents of the psychotropic ingredients are referred to in 
base form, irrespective of the chemical form the addictive substance actually has in the illegal 
preparation. 
The frequency distribution of the content values is usually not normal, but shows a one-sided 
distribution. The dispersion range in all weight categories does not correspond to a Gauss distribution. 
For this reason, it is not the statistical mean value but the median value that is used for stating the 
average content. 
The informative value of the indicator ‘active ingredient content of drugs’ could be further increased if 
each register of the price of the drug seized would be linked to its active ingredient content. The data 
come from different sources and may refer to different periods of time — while the drug prices are based 
on information gathered by police investigations (with a valid date registered), the central analysis of the 
forensic results, which serves as basis for the information on active ingredient contents, provides only 
the date of sample-analysis. In practice, however, it is difficult to link the data. In general, it should be 
noted that in the ‘segment of wholesale trade’ cases, which provide concrete information on prices and 
where it is furthermore possible to seize the drug in order to establish its active ingredient content, 
become known only sporadically. In addition, linking the data requires considerable coordinating and 
recording work, which cannot be made considering the added value to be expected for practical police 
work and the human resources needed to fight drug crime. 
In Germany, the average drug prices and their active ingredient contents are compared once a year. 
The results of the relevant category of active ingredient contents are placed in relation to the wholesale 
drug prices in the framework of a comparison involving several years. This comparative study of the 
data of both series of numbers basically yields results with a higher informative value than those of the 
individual indicators. 
 
4.5. Regional differences 
In the current European political framework borders have become less and less relevant as 
administrative barriers to economic and social interactions. The same is true in drug 
trafficking. The dismantling of some of the traditional border controls in European countries 
has contributed to the integration and change of trafficking routes in Europe. Furthermore, as 
in any other business, drug traffickers adjust quickly to environmental changes that occur 
within a country. Consequently, law enforcement effectiveness is highly increased when there 
is a good knowledge of the geographical distribution of wholesale drug price levels. Since 
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drug trafficking is international, the sharing of this information with other European countries, 
will certainly contribute to more effectively combating drug trafficking. 
The French experience will be given as a case study. Box 6 describes how OCRTIS –
 L’Office Central pour la Répression du Trafic Illicit des Stupéfiants — has in the last three 
years used regional wholesale drug price analysis as an important tool to monitor and combat 
drug trafficking. 
Box 6: Collecting wholesale drug prices in France: understanding drug markets 
(Marc Geny) 
The system to collect regional drug prices: a system available for a decade 
The OCRTIS has collected wholesale drug prices for the main drugs consumed in France since 2000. 
This data collection has been made due to the cooperation of regional and local law enforcement police 
forces, which are in charge of combating drug trafficking. However, until recently, this information was 
only used to build aggregated national data prices series. The information available at regional or local 
level was not used disaggregated. 
An ambitious system, taking into account the complexity of this information 
Assessing the relevant drug prices is complex, because within the same geographical place prices may 
vary due to the quantity purchased, the quality of the drugs (i.e. purity/potency, indicating the 
percentage of cutting agents included in the drugs sold) or, among others, the relation established 
between drug sellers and buyers. Nevertheless, the collection of regional and local prices have the 
objective of supplying law enforcement with a detailed cartography of wholesale drug prices, taking into 
account urban versus rural areas, different transportation networks, and their evolution over time. 
Figure 2: Regions where heroin price are higher/lower than the national median price  
(1st semester 2009) 
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Renewed methodology 
OCRTIS has implemented this data collection exercise three times. The first was in 2006, then in 2008 
and the latest in 2009. OCRTIS has used a specific methodology to collect data at regional and local 
level: 
• a matrix of data collection has been done in advance: combining the requirement to fill in prices 
in euros with comments describing drug supply level and its evolution over time; 
• this matrix has been sent to each local police officer (with the capacity to collect wholesale drug 
prices and to describe the details of drug supply in its area of circumscription); 
• a synthesizing table has been filled in each local police station; 
• an analysis of each region has been made, based on the quartile method (method that reports 
those prices that are the lowest within 25 % of all the prices collected; the next quartile 
corresponds to the price of the 50 % lowest prices registered, then the 3rd quartile is the 75 % 
lowest off all the prices registered and finally, the 4th quartile is the highest price collected in 
this police station); 
• based on these prices a synthesizing map was drawn, allowing a quick overview of prices 
zones and to compare the positioning of each region towards others. It is frequently possible to 
detect the main trafficking routes and consuming areas. 
What has this experience taught? 
This method has allowed a deeper knowledge of regional trafficking routes and entry points in France to 
imported drugs: 
• providing a quick visual picture of drug prices and trafficking routes within the country, regions 
or population agglomeration, combined with information on main transportation routes; 
• allowing to make fast comparisons within localities, regions and cities; 
• giving a better understanding of the dynamics of trafficking networks active in France, showing 
which are the main entry doors by road, airports or ports; 
• providing a good alert system to emerging trafficking routes; 
• providing useful information that helped reorganise law enforcement priorities, and staff 
allocation, taking into account new trafficking routes or changing consumption patterns 
observed in  certain regions/localities. 
 
4.6. Statistical measures used to summarise the collected WDP 
(Catarina Guerreiro and Cláudia Costa Storti) 
One of the objectives of this Pilot study is to discuss the methods used to collect WDP, the 
main goal of this session is to discuss how to organise and report the information resulting 
from this data collection. Taking into account that the ultimate aim of the wholesale drug 
prices collection mechanism would be to provide national information of those prices charged 
in every wholesale drug transaction, within a certain timeframe and in a defined territory, is 
impossible to attain; this analysis should discuss how to overcome this limitation.  
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If prices of licit goods are collected through a sampling process, in a framework of illicit 
transactions it is particularly difficult to know what the prices charged in every single 
transaction were. Different methods are commonly used in order to overcome this difficulty, 
i.e. different methods are used to collect prices of illicit transactions, as discussed in Section 
4.3. These methods should allow us to build price samples. These price samples allow us to 
estimate prices effectively charged in drug transactions, with the support of statistic measures 
which serve to summarise the available information and extrapolate central drug prices 
tendencies. In this session we are going to briefly describe the statistic measures which we 
suggest and that are commonly used in this framework.  
After having collected illicit drug prices, a serious effort should be made to guarantee data 
accuracy at national level. The quality of the statistical results depends upon the quality of the 
data collected and compiled.  
Samples get more representative as the sample size increases (as a proportion of the reality 
it represents). So, in this case, the higher the number of WDP records collected to form a 
sample, the higher the likelihood that statistic measures build on it represent wholesale 
markets correctly. Consequently, it is important to have the possibility to assess the size of 
each sample and, preferably, to compare the size of the sample with the measures they 
represent. In practical terms, in this Pilot study, it is highly advisable to report the number of 
recorded prices, used to build price statistics. Additionally, it is also very useful to compare 
this number with information concerning, for instance, the estimations of the total number of 
wholesale transactions, occurring in each wholesale drug market. In case this information is 
not available, the comparison with the total number of seizures occurring with wholesale 
volumes can also be used as a proxy.  
After having the sample compiled, there are some data management procedures that should 
be implemented. Manual or electronic checks may be necessary to ensure that information is 
correctly compiled. The use of software might be useful to check for anomalies. When 
checking the data included in a dataset, the most common checks that should be done are: 
• out-of-range or inliers values (data values that are quite unlikely to have occurred or 
even if they are likely to have occurred, are still errors); 
• missing values (data omitted due to an error); 
• errors (data incorrectly recorded); 
• duplications (the same observation registered more than once); 
• inconsistencies (prices registered in different places or reporting contradictory 
values). 
Once data collectors have built the best possible sample of wholesale prices, descriptive 
statistics will be used. The aim is to describe prices observed in a region or country within a 
certain period of time. In order to do so, this Pilot study will focus on the type of measures that 
will estimate ‘central tendencies’.  
In this study, it was decided to use five main statistical measures to describe central 
tendencies. These measures are the minimum and maximum prices observed in the sample, 
the mean (or average), the mode and the median. Taking into account the framework where 
these measures are going to be used, their main strengths and weaknesses are briefly 
described.   
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Minimum — the smallest value registered in the sample:  
• clearly understood by different types of readers; 
• provides an idea of the ‘most common corridor’ where prices float; 
• does not give much information on the most common prices;  
• useful to detect trends changes; 
• easily influenced by extreme values. 
Maximum — the largest value registered in the sample: 
• clearly understood by different types of readers; 
• gives an idea of the ‘most common corridor’ where prices float; 
• does not give much information on the most common prices practiced;  
• helpful to detect trends changes; 
• easily influenced by extreme values. 
Mean (average) –– it is the arithmetic mean: 
• clearly understood by all, since it is the most common central tendency statistic; 
• quick assessment of the distribution symmetry (verifying if it is smaller or larger 
than the median); 
• vulnerable to extreme values. 
Mode — the most reported value: 
• represents the price charged more often, so it can be a useful descriptive 
variable; 
• it is a price that was charged ‘in reality’; 
• not sensitive to the existence of extreme values; 
• possibility of more than one mode in the same sample — in this case, it is useful 
to have information about the values of the existing modes;  
Median — once the price values are ordered from the smallest to the largest value, the 
median is the value that splits the ranking into two equally seized groups (50 % of 
cases in each side). When there is an ‘even number of observations’, the median 
is the average of the two prices of the centre of the distribution: 
• represents the price charged when the number of times that smaller prices were 
charged equals the number of times higher prices were charged; 
• comparing its value to the mean shows the symmetry of the distribution; 
• not sensitive to the existence of extreme values;  
• it was less commonly used some time ago by national reporting institutions, but 
currently a growing number of countries is using this measure.  
The utility of these statistical measures increases substantially when they are reported 
together. For example, the meaning of the mean is increased when combined with the 
information given by the median: a very high mean with a much smaller median tell us that 
this average price is skewed by very high and uncommon maximum prices.  
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Typical prices 
Finally, it should be mentioned that in this field it may happen that price information is not 
always systematically collected. There are some countries where the estimates of wholesale 
drug prices are based on key expert’s opinion. Normally, these prices are known as ‘typical 
prices’. This information is interesting to be reported, since it provides qualitative assessment 
of price levels, but should also be clearly identified as such and considered as 
complementary information to the statistical data reported.  
Taken into account the different nature of these data sources (expert’s opinion versus 
statistical information), it is important to identify which one is being reported. Consequently, it 
is requested that when ‘typical prices’ are reported, that data source is clearly identified in the 
reporting template, instead of filling in the fields available for the statistical measures with 
incorrect data. The opposite also holds true. 
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5. Data availability in Europe, at national level 
By drug, country, size of the transaction and periodicity 
In order to assess the feasibility of launching the collection of wholesale drug prices, the 
EMCDDA has sent a questionnaire to the EU Member States, candidate countries, Croatia, 
Turkey and Norway (see Annex 1). Answers depict the situation that existed in 2010. This 
project benefited from the support of the Reitox national focal points, which guaranteed that 
the best national institution could contribute to the project. Out of the 30 countries receiving 
this questionnaire, 24 countries replied (14) (between 2009 and the beginning of 2010). Annex 
1 presents the template of this questionnaire. Annex 2 presents the summary tables with 
national replies. 
European countries collecting WDP 
Map 1: Countries collecting wholesale cannabis resin prices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Europe, out of this group of 24 reporting countries, only Ireland does not collect wholesale 
drug prices. Hungary collects WDP but does not have an organised database. Table 1 of 
Annex 2 presents results detailed by the main drug. Map 1 presents the current situation 
concerning the collection of cannabis resin wholesale prices. There, it is shown that most of 
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the answering European countries collect cannabis resin prices. Concerning cocaine and 
ecstasy, all countries but Ireland collect these prices. Heroin WDP are collected in 21 
reporting countries (out of the 24 answering countries). Ireland, Estonia and Finland do not 
collect heroin prices. Wholesale prices of amphetamines are not collected only in the Czech 
Republic, Ireland, France, Cyprus and Portugal.  
Starting year of the national collecting procedure 
Table 2 of Annex 2 shows when countries started to collect these prices. The situation varies 
widely when different drugs and/or countries are considered. In Germany, wholesale cannabis 
resin or heroin prices have been collected since 1975. In Turkey, these prices have started to 
be compiled only in 2007. While in most countries these prices are published once a year, 
there are five countries that may report twice a year (CZ, ES, IT, LT, and TR). Additionally, 
three countries report these prices quarterly (CY, NL and the UK). 
Countries where WDP are ready to be published by the EMCDDA 
Annex 2 also shows those countries where WDP could be currently published by the 
EMCDDA. Although there are some differences within the same country for the different 
drugs considered, out of the 24 reporting countries, in 19 it is possible to report wholesale 
drug prices in the near future (BE, CZ, DK, DE, ES, FR, IT, CY, LT, NL, AT, PT, RO, SI, FI, 
SE, UK, HR and TR). Map 2 shows those countries where it is currently possible to publish 
cocaine wholesale prices.  
Map 2: Possible to publish wholesale cocaine prices, in the near future 
 
 
 
 
 
 
 
Countries using alternative definitions to wholesale drug prices 
The EMCDDA asked national experts whether alternative definitions of wholesale drug prices 
were used in their European country, as compared to that one suggested by the EMCDDA. 
Out of the 24 answering countries, none is using an alternative definition. They all agreed that 
wholesale drug prices are those charged in transactions of large volumes. It was agreed and 
that the reference to a minimum of approximately 1 kg (1 000 units) threshold is adequate. It 
was decided that lower than 1 kg transactions (between 0.5 kg and 1 kg; and between 500 
units and 1 000 units) should be accepted to take into account that in some countries, 
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wholesale transactions may start at a lower weight/number or units, due to the existence of 
smaller markets. 
However, there is some discussion of what might be considered to be the lower limit of 
wholesale drug transactions for different drugs. Since dimension and habits of use vary 
across European countries, the lower limits of wholesale drug transactions may differ across 
countries. Chapter 4.1. discusses this topic. 
Methods used to collect wholesale drug prices 
As described in Section 4.3, there are several methods used to collect wholesale drug prices. 
The EMCCDA asked national experts what the methods are most commonly used by national 
law enforcement to collect this information. National characteristics may drive countries to 
prefer some methods to others. For instance, the characteristics of drug trafficking and drug 
use in a country, the legal frameworks, policy priorities, the organisation of the national law 
enforcement systems, and last but not least, the volume of resources allocated to this activity 
are factors that introduce wide diversity in each country’s operational collecting mechanisms. 
Since there is consensus among national experts, that the methodology used does not 
considerably vary across drugs, a common questionnaire was drafted. This section presents 
the results.  
Figure 3 summarises the results of the 23 countries that answered this question. The first 
conclusion we arrive to is that most of the countries combine different methods to collect 
wholesale drug prices, reducing the risk that prices become strongly biased. Second, all 
countries interrogate arrestees in order to collect wholesale prices (more than 80 % of the 
countries frequently use this technique, while close to 20 % do it seldom). The use of 
informants and documentation seized are also frequently used, as well as other intelligence 
material collected (more than 50 % of the countries use it frequently and 40 % use it seldom). 
Conversely, academics surveys and drug users counselling are techniques hardly ever used 
by most of the countries. 
Figure 3: Methods used to collect wholesale drug prices 
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Statistical measures used to compile information on wholesale drug prices at national 
level 
Section 4.4 discusses the main statistical methods usually used to summarise information on 
prices. 21 countries answered this question. From this group, seven countries (15) compile 
information using a complete set of statistical measures. These countries provide the 
minimum and maximum prices, average prices and either the mode or the median. With these 
statistical measures, it is likely that a good estimate of the prices in each of these countries is 
provided. In order to increase the representativeness of these statistics, the more often these 
prices were collected, the better. It can also be mentioned that the use of the median gives a 
better representation of the prices in every country. However, according to the available 
information, the number of countries that have this measure available is still small. 
Nevertheless, it is in the interest of this project that national reporting institutions will develop 
this tool. At the end of this Pilot study, there were a growing number of countries that started 
to calculate the median (DE, CZ, FR, TR, PT and PL). 
In the remaining countries, the situation varies considerably from country to country. The most 
frequently available measure of wholesale drug prices is the minimum and maximum prices. 
Besides being available in the seven countries previously mentioned, they are also published 
in eight other countries (16). In BE, DK and DE they are also published with the mean, which 
gives a better understanding of data variation. These statistics can, however, be easily 
influenced by extreme values that greatly influence averages. There are countries where only 
the minimum and the maximum values were published. This is the case in IT, AT, RO, SI and 
SE. However, in Italy and Austria, concrete measures are being taken in national collecting 
data institutions, i.e. police forces, to improve the situation, among other reasons, as a 
consequence of this project. In Finland, the minimum and maximum values are reported with 
the typical value.  
There are three countries (EE, CY and HU) where typical values of wholesale drug prices are 
the only measure available. In these countries there is room for improvement concerning 
more of a statistically oriented production. 
Relating purity/potency to wholesale drug price data 
Out of the 23 countries that answered the questionnaire in 2010 there were nine countries 
that relate drug prices at the wholesale level with their correspondent purity level, as showed 
in Map 3. These countries are CZ, DE, ES, FR, PL, PT, SK, UK and TK. In some countries, 
these data only exist for some drugs (for instance, in the UK there are no data on the THC 
content of cannabis). Since then, other countries such as AU have also started to compile 
data on wholesale drug purity. 
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Map 3: Countries that relate purity data to wholesale prices in 2010 
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6. The Questionnaire on wholesale drug prices 
In June 2009, Europol, SOCA and the EMCDDA met in The Hague to draw a first draft of the 
common questionnaire to collect wholesale drug prices in Europe. This template was 
analysed and tested with real national data for 2008, by the European Expert Group on 
Wholesale Drug Prices. 
In June 2010, an expert meeting was co-organised by the UK focal point, SOCA and 
EMCDDA. Europol, as well as all the other 26 national representatives from 20 countries (BE, 
CZ, DE, EE, ES, FR, IE, IT, CY, LT, HU, NL, AT, PL, PT, RO, SK, UK, HR and TR) 
contributed to discuss the template and its first results. The main aim of this meeting was to 
improve the template of wholesale drug prices, after taking into account the first exercise of 
real data collection. The final template on wholesale drug prices is presented in Annex 3. 
6.1. The main Questionnaire on wholesale drug prices  
Annex 3 presents the main template to collect wholesale drug prices in Europe. It takes into 
account the information that was readily available in Europe and the minimum requirements 
of this dataset. The situation experienced in different countries varies widely in Europe. 
Consequently, the template adopted intends to accommodate these situations. On the one 
hand, it aims to provide a tool that allows to make a complete and meaningful report, 
answering to the needs of an advanced wholesale data price collection system. On the other 
hand, it also aims to allow countries with less developed data collection mechanisms to report 
in a framework where these reporting limitations are clearly identified.  
It should be emphasised that when this Pilot study was written, there were a large number of 
countries planning to revise or already revising their internal law enforcement practices in 
order to comply with the requirements set by the questionnaire. According to the reported 
practices, eight countries introduced changes in their law enforcement practices or 
subsequent procedures. In France, the Office Central pour la Repression du Trafique des 
Stupéfiants (OCRTIS) has linked wholesale drug prices to purity. In Austria, the Criminal 
Intelligence Service, MOI, improved the Internet-based application (which links local police 
stations to the central police office) with the objective of relating purity to prices. In the Czech 
Republic, the national focal point has made an agreement with national law enforcement to 
relate wholesale drug prices to purity. In Italy, Belgium and Hungary, national law 
enforcement offices are waiting for the final wholesale drug prices questionnaire to adjust 
national procedures accordingly; In Lithuania and Turkey, training has already started to be 
given to local law enforcement agents.  
The main wholesale drug price questionnaire includes seven main sub-tables. Sub-table 1 
records the date of data transmission to the EMCDDA; which country or region and period of 
time it concerns and; finally, provides information concerning the reporting agency. Sub-table 
2 provides detailed information concerning the contact person in charge of sending 
information to the EMCDDA, in case there are doubts with the information reported. 
Sub-table 3 allows national authorities to report drug prices associated with wholesale drug 
transactions. In order to define criteria that are objective and easily to make operational, it is 
considered that wholesale drug transactions are those occurring when the volumes traded are 
approximately 1 kilo(or 1 000 units) and above, and taking place within the national 
jurisdiction of the reporting country. In any case, and no matter the volume traded, prices 
reported have to correspond to those charged to each kilo (or each 1 000 units). In another 
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words, the unit of count is always the kilo (1 000 units) price, even when the weight of the 
transaction differs from that volume. 
This questionnaire identifies 12 drugs, the prices of which are considered relevant to be 
periodically reported. They are cocaine, crack cocaine, brown heroin, white heroin, opium, 
methyl amphetamines, ecstasy, LSD, amphetamines, cannabis resin, herbal cannabis and 
skunk. Nevertheless, in order to accommodate future drug market developments and the 
emerging of other drugs, it is possible to report prices of other drugs, if identified. 
When reporting prices for a certain drug, there are some basic rules to respect: 
1. WDP should only be reported if relevant information exists. In case there is no 
relevant information available, blank spaces should le left; 
2. WDP reported should concern the price charged to each kilo (or 1 000 units), even 
when the underlying transaction had a different weight or if there is information 
concerning the total value of drugs traded. 
3. WDP reported should represent prices charged in a certain country. It is also possible 
to report regional or local prices, but in this case it has to be clearly identified in the 
left top of the table, in the field ‘country (or region)’; 
4. WDP reported should concern prices recorded over one year within a country (or 
region). It is possible to report prices that concern other periods of time, if clearly 
identified in the top left of the table, in the field ‘reporting period’; 
5. In case the national currency is not the euro, prices should be reported in the national 
currency, in the respective field available. In these cases, it is also possible to report 
prices in Euros, but the exchange rate applied should be the official one calculated by 
the European Central Bank, for the concerned period of time 
(http://sdw.ecb.europa.eu/browse.do?node=2018794). When the national currency is 
the euro, prices should be registered in the fields (Euro); 
6. The purity level (or the THC content in case of cannabis) observed in the drugs 
traded in wholesale transactions should be reported; 
7. Whenever information exists, prices and purity reported should be stratified according 
to the weight of the underlying wholesale transaction, in order to provide information 
on quantity discounts. The weight ranges defined are: 
• Consignments above 0.5 kilo but inferior to 1.5 kilos (more than 500 units but 
less than 1 000 units); 
• Consignments equal or above 1.5 kilos but inferior to 10 kilos (equal or more than 
1 000 units but less than 10 000 units); 
• Consignments equal or above 10 kilos but inferior  to 100 kilos (equal or more 
than 10 000 units but less than 10 000 units); 
• Consignments equal or above 100 kilos (from 100 000 units onwards). 
8. If it is not possible to stratify wholesale drug prices according to the above-mentioned 
weight ranges, price data should be reported in the column available for this purpose 
(column 9); 
9. To report drug prices and drug purity (potency), the following statistical measures 
should be provided, whenever available: minimum value, maximum value, mean 
(average), mode and median. 
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10. The number of incidents that served as the basis to calculate the statistical measures 
provided should be indicated, when available. 
11. In case there is information about an experts’ consensus on minimum, maximum and 
mode prices (the most commonly observed prices), these prices should be reported. 
There are fields specifically available to report this information. 
Sub-table 4 allows the reporting of information on what the most frequently used methods are 
to collect information on wholesale drug prices in that country over the concerned period. 
Section 4.3 describes these listed methods in detail: 
• drug purchases; 
• informants; 
• interrogation of arrestees; 
• debriefing convicted prisoners; 
• wire-tapper registers; 
• other covertly collected audio material; 
• documents seized by law enforcement; 
• operational intelligence material; 
• open source information (internet and public forums); 
• academic and social surveys; 
• market price appreciations from experts (police and academic). 
Since the methods used to collect drug prices do not differ substantially across drugs, it was 
considered sufficient to use the same table to report this information once. However, since the 
different methods used may allow collecting data with different degree of reliability and with 
specific types of bias, it was considered appropriate to collect qualitative results. So, instead 
of aiming at counting the number of times that each technique was used to collect prices, the 
data collector is given the possibility to report the frequency with each technique was applied, 
within the criteria ‘frequent’, ‘seldom’ and ‘never’. This information will allow understanding if 
there is any potential dominant bias in the reported data. 
Sub-table 5 gives the possibility to report changes in the collecting methodology which may 
impact the comparison of the reported data with data available in dataset. Sub-table 6 allows 
the clarification of reporting methods different by those set by the EMCDDA. Finally, sub-table 
7 allows the reporting institution to explain and provide contextual information about a 
particular trend or an emerging market influence with impact on wholesale drug prices 
reported. 
6.2. The European Drug Wholesale Price Sample Submission 
Questionnaire  
In order to make data wholesale drug collection procedures more flexible, a template for the 
European Drug Wholesale Price Sample Submission Questionnaire was defined (see Annex 
4). This template shall also allow countries to provide qualitative information about wholesale 
drug prices or detailed information on a specific wholesale price related issue.  
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In a framework where this questionnaire has been conceived to allow data providers to 
describe specific situations when WDP have been collected, the theme of each round of data 
collection should be pre-agreed and clear objectives should be set, in order to make these 
data meaningful. These objectives can be different according to the needs. Examples of 
possible uses to the European Drug Wholesale Price Sample Submission template are: the 
description of the most common methods used to collect wholesale drug prices; the 
description of wholesale drug prices in regions where prices are remarkably different from 
national averages (suggesting some regional peculiarity); the analysis of wholesale drug 
prices collected with the support of a specific law enforcement technique (allowing to assess if 
this technique results in a specific price bias), etc. 
This questionnaire has three main parts. Part 1 allows the overall characterisation of the data 
reporting exercise. This part is conceived to allow reporting information about submission 
date; country or region concerned, as well as the date when the exercise of price collection 
occurred; the agency which collected prices and; finally, information about the contacts of the 
reporting person. 
Part 2 aims at allowing the report of information about the general circumstances surrounding 
the exercise of wholesale drug price collection. In order to do so, the collection technique(s) 
used to collect wholesale drug prices is (are) identified in the field ‘data collection methods’. 
Since there are times when more than one method is used, it is possible to report these 
techniques in the fields ‘data collection method’. Then, the description of the main drugs to 
which price information exists is to be reported; as well as the total volume of drugs involved. 
In case information on purity (potency) exists, it should also be reported. This questionnaire 
requests information about the type of evidence collected to support price information for 
each drug. Furthermore, space is given to provide a brief description of the incident of the 
investigation. Here, information about the countries involved, trafficking locations, methods of 
transporting drugs and possible seizures occurred, as well as the nationality of traffickers and 
level of trafficking conducted should be provided. Part 2 also provides a field to report 
information about the drug price insight achieved during the concerned investigation. Part 2 
ends by requesting authorisation to publish this information on the EMCDDA website. 
Part 3 is devoted to describe the information on wholesale drug prices collected in this 
investigation. There, it is possible to provide the minimum and maximum prices, as well as the 
price applied per kilo (or 1 000 units). There is space to report the currency in which 
transactions were made, as well as the total weight of the transaction and the specific weight 
of single doses. Again, it is desirable to report which methods were used to collect prices for 
each drug. In case prices reported implied some calculations, its methods used can briefly be 
described. Part 3 ends by requesting authorisation to publish this information in the EMCDDA 
website. 
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7. Results from two rounds of data collection (2008 and 2009 
data) 
Annex 5 presents the WDP data collected through the European network of experts on 
wholesale drug prices, for 2008 and 2009. Some preliminary conclusions can be drawn from 
these two experiences of data collection. However, these conclusions need to be interpreted 
carefully since this was an experimental project and, consequently, both data providers and 
collectors were passing through a ‘learning by doing’ process. Nevertheless, it should be 
noted that data collectors are planning to adjust or have already adjusted their collecting 
procedures in order to better comply with the data requirements and templates established 
within this Expert group. 
The main conclusions concerning data availability drawn from these reporting exercises are: 
1. There is a broad consensus about the operational definition of wholesale drug prices 
across Europe. This definition is used both by operational data collectors and by police 
analysts. This shared definition facilitates the implementation of this data collection 
exercise across different European countries and its use afterwards; 
2. A considerable number of countries reported information on wholesale drug prices to 
the EMCDDA: 
• 18 countries (AT, BE, CZ, CY, DE, ES, HR, LT, PL, PT, SK, UK, IT, NL, FR, CY, 
TR, PL) provided wholesale drug prices either for 2008 or 2009;  
• 12 countries provided information filling in the main questionnaire with data for both 
2008 and 2009; while there were three countries that reported information 
concerning 2008 only (until the closing of this report); 
• six countries provided examples of WDP collection exercises. 
3. The volume of information available differs considerably by drug: cocaine, brown heroin 
and cannabis (resin and herbal) are those drugs with more information available;  
4. The comparability of wholesale drug prices across countries is still limited, because 
methods of data collection vary and different countries face different limitations. Chapter 
VIII describes national collecting procedures with concrete examples. Nevertheless, the 
data reported provides sensible information and allows to sketch a picture of wholesale 
drug prices in Europe; 
5. Six countries report wholesale drug prices stratified by the volume of the underlying 
transaction (CZ, DE, ES, FR, PT and UK). There are two additional countries that have 
information ready to be reported on purity stratified by the volume of underlying 
transaction (LT and SK), but prices are still unstratified at the level of 1 kg transactions. 
There are five countries which can report only aggregate wholesale drug prices (IT, CY, 
LT, AT, TR). However, within these countries, some have already either started or 
announced the intention to adjust their collection system in the near future (AT, IT and 
TR); 
6. The number of countries reporting purity varies from drug to drug, but a considerable 
number of countries has information on purity at wholesale level for some drugs: nine 
countries reported cocaine purity (AT, CZ, DE, ES, FR, LT, SK, TR and UK) and brown 
heroin purity (AT, CZ, DE, ES, HR, FR, SK, TR and UK). Concerning cannabis, six 
countries reported the potency of herbal cannabis (CZ, DE, ES, FR, SK and TR) while 
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only 3 reported the THC contend of cannabis resin (DE, ES and FR); 5 countries 
reported ecstasy purity (AT, CZ, DE, HR and TR); 
7. All countries reported the minimum and maximum prices as measures of the WDP and 
purity observed. Most of the time, these measures were complemented with information 
on mean prices/purity (FR is the only country that does not report the mean). 
Information about the mode is reported in some countries (UK, BE, AT). The median 
has started to be provided frequently concerning 2009 data (DE, CZ, FR, TR, PT and 
PL). 
8. 10 countries reported the total number of incidents to calculate drug prices, for almost 
all drugs; 
9. Two countries reported prices based on the experts’ consensus. In both cases, these 
prices were reported in addition to those prices calculated by statistical measures.  
The main conclusions concerning wholesale prices and purity reported show some 
interesting features. The methods to collect and report drug wholesale prices differed 
substantially across countries in these two reporting exercises (2008 and 2009). Furthermore, 
even within the same country, there were a few cases where changes in statistical methods 
were reported. Consequently, conclusions obtained from these exercise have to be taken with 
much caution. Some preliminary analysis can be applied to some types of drugs. Box 7 
presents an example of the type of analysis this data may permit in the future.  
 
Box 7 — Cocaine wholesale drug prices in Europe 
Table 7.1 shows the best comparable WDP data for 2009, reporting wholesale drug prices verified in 
transactions with volumes varying between 0.5 kg and 1.5 kg. This table also considered countries that 
reported prices but could not associate them to the precise weights transactions. The reason to 
compare these prices with those charged in ‘small wholesale transactions’ is that since smaller 
transactions happen more frequently in drug markets, it is more likely that when there are prices 
available, but not clearly identified, they were charged to smaller wholesale transactions. The higher 
availability of prices charged in smaller transactions is also shown in the number of incidents reported. 
From there, it can be seen that countries collect more information on prices charged in ‘smaller’ 
wholesale transactions. 
Table 7.1 presents the cocaine wholesale prices ‘central tendencies’ in 2009 and 2009. Focusing the 
analysis in 2009 data, we arrive to a certain number of interesting conclusions. 
In 2009, in the 14 European reporting countries, the price of 1 kg of cocaine (17) varies between EUR 
20 000 and EUR 66 751. When measures of central tendencies are taken into account, prices can be 
grouped. Using the median whenever available (BE, FR, TR, DE and CZ) or otherwise the mean (ES, 
LT, IT and CY) and in the UK case the mode, we conclude that central prices varied between EUR 30–
35 000 in six countries (AU, BE, ES, FR, PL and TR). There were two countries (DE, LT) where central 
WDP varied between EUR 35–40 000; while in the IT and the UK, these prices varied in a higher range 
(EUR 40–50 000); two countries estimate that central tendencies were higher, varying between 
EUR 50 000 and EUR 60 000 (CZ and CY). 
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Table 7.1 — Cocaine wholesale drug prices — summary table (0.5 kg–1.5 kg consignments) 
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From this data sample, and taking into account the 2008 and 2009 reported data, it is difficult to arrive at 
solid conclusions concerning the application of quantity discounts in the cocaine market. Data reported 
by Germany for 2008 suggests that prices tend to decline with the increase of transaction volumes. The 
same holds true in France in 2009, even if the average purity seized increased. So, in France the purity-
adjusted prices revealed a strong decline with higher volumes traded. However, in another country with 
available data, the Czech Republic, prices reported do not confirm this tendency. Therefore, we cannot 
identify a clear pattern concerning the application of quantity discounts in cocaine markets in Europe. 
Table 7.2 presents retail and wholesale drug prices in 2008. This analysis has to be interpreted with 
caution since data are not always reported by the same institution or collected with the same 
techniques, which may result in unknown estimation bias. 
Taking this into account, Table 7.2 shows an accrue estimate of the profit margins attained in European 
retail markets. This estimation is based on the percentage difference between retail and wholesale drug 
prices. This data reveals that profit margins of retail cocaine markets varied widely in Europe. These 
preliminary estimates suggest profit margins varying between close to 20 % in Italy and 152 % in 
Lithuania, in 2008. The most common values, however, are close to 50 %. 
Table 7.2 
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8. National overviews of collection procedures 
This section gives a brief overview of how different countries collect wholesale drug prices 
and organise the reporting procedures within the different institutions in charge of collecting 
different types of information.  
8.1. The Austrian collecting procedures   
(Christian Mader) 
In Austria, data from drug cases is transmitted electronically to the Criminal Intelligence 
Service Austria (CIS) — the Ministry of the Interior — by a web application within the ‘Intranet’ 
(i.e. an internal Internet to secure data transport). Forwarding data is one of the CIS-officers' 
reporting tasks. 
In principle, all statistical data are collected as a by-product of criminal investigations. There is 
a big concern with data quality because the main goal of statistical data is to be meaningful 
and informative. Since 2000, all statistical and individual data contained in reports and 
complaints for violation of the Austrian Narcotics Act has been recorded electronically, passed 
on and analysed.  
Close to 1 000 Austrian law enforcement stations register these data electronically and send it 
to the Criminal Intelligence Service Austria (CIS) — Ministry of the Interior. The 
communication system is based on a  web application, developed in an ‘Intranet’ framework 
(i.e. an internal Internet to assure secure data transport). In order to implement a closed 
Internet framework, a secure line was developed to link the Ministry of the Interior, allowing 
this Ministry to compile and store this data. Within the Ministry, this task is performed by the 
Unit IT-MS (information technology, management and services). Subsequently, this 
information is made available to the CIS. Within the CIS, there is a unit in charge of screening 
data, to verify and rectify discrepancies (upon consultation with the local service). Person-
related data are recorded and used for criminal investigations. Following this procedure, 
approximately 24 000 complaints in the field of drug-related crime are handled electronically 
per year. Subsequently, CIS analyses this data. At this stage, information is split into either 
‘statistics’ or ‘personal data’. Statistical data remains in the database, being available for 
analyses. This set of data is the basis of the Annual Narcotic Crime Report.   
The entire database (statistical data and individual data) is electronically forwarded, via the 
‘E-Government’ system, to the Federal Ministry for Health. Extracts of this database are then 
further relayed to the OBIG (Austrian Reitox Focal Point) and then transmitted to the 
EMCDDA. 
 
Step 1 — Local police officers compile files for prosecution: 
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The electronic system is available for each police officer in Austria (approximately 23 000). 
Police officers compile each report for prosecution.  
 
Step 2 — Data are electronically reported to CIS — Upon completion of the report, the 
system forwards the information in real-time via a secure line to the Ministry of the Interior, 
where data are stored in a database by the unit IT-MS and made available to the CIS Austria. 
 
 
 
 
 
 
 
Step 3 — Data checking — The sub-department 3.5 of the CIS screens the data, detecting 
rectifying discrepancies (upon consultation with the local services). Person-related data are 
recorded and used for criminal investigations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 4 — Data analysis  
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As the Austrian data protection law is very strict, the CIS organises available data. Data are 
split into ‘statistics’ or ‘personal data’. Statistical data remain in the database and are always 
available to be analysed. This data will contribute to the Annual Narcotic Crime Report. 
Individual-related data are erased from this database. 
 
Step 5 — Reporting results  
 
 
 
                   
           
 
 
 
 
 
 
 
 
 
 
 
 
 
The entire dataset (statistical data and person-related data) is electronically forwarded to the 
Federal Ministry for Health. Extracts from this evaluation are then further relayed to the OBIG 
for onward transmission to the EMCDDA.  
 
The main advantages of the system are: 
1. Each individual-related data record is tagged with an area-specific personal identifier, 
allowing a cross-analysis of personal data. It also complies with the requirements of 
data protection. 
2. Multiple and flexible breakdowns of the database are possible. Then, their analysis is 
used for steering human resources of criminal police, allowing the construction of the 
required statistics.  
3. This process facilitates the creation of the Annual Drug Report of Austria (available 
on the Internet, www.bmi.gv.at/Kriminalpolizei — link ‘Publication’). 
4. Timely delivery of data. 
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An example of possible data use: Austrians charged with drug criminal offences: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: The data collecting system upgrading: at any time! 
 
Innovative systems have to be easily upgraded, whenever required. Times, crimes and 
consequently, requirements change fast. As such, in 2009, the Austrian data collection 
system registered an upgrade: drug prices (retail and wholesale) and their related purity was 
inserted. In order to do so, a new template was created in the IT programme filled by local 
police officers: 
Note: Strassenhandelspreis = retail price, Großhandelspreis = wholesale price, Reinheit = purity. 
 
With this system, it is only necessary to collect key data to be reported to prosecution. The 
statistical data treatment is automatically realised by the system. Subsequently, an IT 
2008                                                 
Austrians charged w ith criminal offences under 
sections 27-32 Narcotics Act
13121
1142 794
§ 27 Narcotics Act
§§ 28 and 28a Narcotics Act
other criminal offences §§ 30-32 Narcotics Act
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application builds the required statistics (mean, median and mode). This application is 
generally applicable to all data fields. Data is a by-product of criminal investigations — the 
system performs the analysis.  
 
The benefit of having invested in the current Austrian automated system of data collection 
system has been recognised as being worded since it has benefited law enforcement 
agencies, health institutions, policy makers and international organisations.  
8.2. The Belgian collecting procedures  
(Pascal Garlément) 
Background information — the Belgian institutional cooperation 
In Belgium, there are three power levels that are in charge of collecting wholesale drug prices: 
the federal government, the three regional governments (Flemish, Brussels and Walloon 
regions) and the three communities (Flemish, Walloon-Brussels and German-speaking 
communities). With regard to the gathering of information transmitted to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA), one national focal point 
coordinates the actions of three sub-focal points, organised by the communities. The police 
also cooperate with the national focal point, among others, for the drawing up of the Belgian 
annual report. The communication of the prices is part of the cooperation between the police 
and the national focal point. Although information regarding retail price provided by the police 
is completed with information in reference to the prices gathered by the sub-focal points, 
when it concerns wholesale prices (defined for this project as those concerning quantities of 
illegal drugs exceeding 500 grams) only police services are able to provide the requested 
information. 
Police organisation elements influencing price collection  
The Belgian police is organized on two independent but integrated levels. Integrated tasks 
relate, for instance, common recruitment, common training and the use of a single criminal 
data base. Beside the central service in charge of the coordination, the federal judicial police 
counts 27 decentralised units established in each of the 27 judicial districts where legal 
proceedings are organised (under guidance of a public prosecutor). The federal police also 
count some first line units that are entrusted with recording violations of the legislation on 
illegal drugs (railway police, highway police, waterway police and airport police). The 186 
local police units are also involved in the fight against the sale, production and trafficking of 
illegal drugs. 
On average, police services report more than 40 000 violations of the legislation on illegal 
drugs to the public prosecutor. The majority of these violations concerns possession or retail 
sale of drugs (about 85 %). In 2009, the central drugs unit only registered 583 seizures of 
more than 500 grams. However, Belgium has a huge consumption market of illegal drugs, 
and most of the drug seizures (in particular in the ports and airports) are in transit to another 
country. Indeed, almost 84 % of the persons intercepted in possession of drugs at the 
Brussels Airport do not live in Belgium and/or declare that Belgium is not their final 
destination. The fact that Belgium is an important transit country influences the collection of 
prices. When the police seize drugs that are intended to be sold in another country, the 
judicial investigation (that allows estimating the price charged) is often led either in the 
destination country or in the origin country where seized drugs come from. 
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Elements influencing the collection of information regarding purity 
Belgium has a National Institute of Criminology that is under the auspices of the Ministry of 
Justice, which is entitled, among others, to make the analysis of drugs. This institute is not the 
only laboratory where judicial authorities can request the analyses of seized products. 
Numerous other laboratories (such as those from hospitals, universities and private 
laboratories) can be requested by magistrates to carry out drug analyses. The reports of 
these analyses are transmitted to the magistrate who adds the findings to the judicial file. The 
police service in charge of the investigation under the guidance of the magistrate is usually 
informed about the findings of the analysis but never obtains a copy of it. The findings of 
many analyses carried out on request of magistrates are thus not centralised and it is 
therefore impossible to publish representative findings. 
The collection and use of prices in Belgium 
For operational purposes 
The price of drugs is mainly used for operational purposes. An actual and accurate 
knowledge of the prices is a necessity for the credibility of undercover operations. This 
knowledge is also useful when calculating the value of the illegal property that is confiscated 
by a dealer or trafficker. This knowledge, however, is only useful if it is up-to-date and 
detailed. An annual collection of prices does not meet this requirement of actuality and detail. 
For such a purpose, the determination of a price occurs by means of a punctual and accurate 
request to investigators who have been confronted with such a situation. 
For strategic purposes 
The Belgian federal police does not use prices as a strategy indicator, due to several reasons 
(e.g. size of the country, role of the country in trafficking, lack of reactivity of the price). 
Nevertheless, as (general) knowledge of the price of drugs remains crucial, the central drugs 
unit of the federal police uses a cheap procedure for the collection of this (general) 
information. Once a year, the federal and local drug investigators are requested to 
communicate price data (about minimum, maximum and common indicators) of the drugs 
they dealt with in their judicial district, both wholesale and retail price. In order to fulfil this 
obligation, investigators rely on the information from their inquiries, phone tapping and 
contacts with consumers and dealers. 
The information is communicated by the investigators through the 27 information crossroads 
established in each judicial district. This working method allows, first, each district to gather 
the data received from the federal and local units and, second, the central level to gather the 
data per region or at national level. Beside the communication of data to the national focal 
point, the information is also communicated to the 27 information crossroads that have 
contributed to data collection. 
Future developments 
In order to give the EMCDDA a chance to carry out this project successfully and to evaluate if 
the collection of information regarding the wholesale prices is likely to contribute to a better 
understanding of the drug market, the Belgian federal police is ready, for a limited period in 
time, to improve the collection of information relating to wholesale prices. 
 
During the second half of 2010 and in 2011, the central drugs unit will systematically gather 
data indications about the prices for seizures exceeding 500 grams, and information about the 
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origin and destination of the drugs or the characteristics of the criminal groups that are 
involved in the deals. At the end of 2011, a cost-benefit analysis will be carried out in order to 
decide whether this information gathering procedure can be maintained or if the former 
procedure should be implemented again. 
8.3. The collecting procedures in Cyprus 
(Elena Demosthenous) 
Methodology of data collection:  
The Drug Law Enforcement Unit of the National Police Department is the main actor in the 
collection of wholesale drug prices in Cyprus. The collection began in 2004 when the Cypriot 
national focal point set the requirement of monitoring drug markets, in order to have a better 
understanding of traffickers’ activities. The monitoring and recording of wholesale prices has 
contributed to the improvement of the strategies designed to combat illegal trafficking by 
some key actors (i.e. policy-makers). In addition, among other data concerning illicit supply of 
drugs, wholesale prices are reported from the DLEU to the UNODC through Annual report 
questionnaires. 
Concerning the collection of wholesale prices, there is a DLEU department in each district of 
the island that collects these prices, depending on available information. This data collection 
is based mainly on police undercover activities, seizures, arrests and also on informants. 
Wholesale prices are collected on a quarterly basis. However, the prices vary depending on 
the type and quality of the substances. Due to the fact that no purity testing is carried out by 
the State General Laboratory, this is the only source available, with regards to the quality of 
an illicit substance.  
The data collection mechanism of wholesale drug prices could be further developed in order 
to meet European standards. First, the fact that there are few numbers of seizures involving 
huge amounts of drugs prevents an extensive analysis of these prices (i.e. minimum, 
maximum, mode, etc.) (18). Consequently, more investment in this area would be desirable. 
Secondly, the lack of an electronic system for the recording of wholesale prices database is 
also a constraint. This absence prevents both quick access to information and effective 
comparison between national and European wholesale price levels. 
Steps forward 
In January 2011, the DLEU has begun applying the same methodology suggested by the 
EMCDDA questionnaire on wholesale drug prices. This is an important step forward, since it 
harmonises collecting procedures with European standards, allowing more accurate 
comparisons with other countries. Difficulties in collecting procedures will are going to be 
discussed as soon as these questionnaires are going to be completed for the first time. 
8.4. The Czech Republic collecting procedures 
(Roman Pesek, Bretislav Brejcha and Jiri Vopravil) 
 
The system of price data collection 
In the Czech Republic, there are three levels of police forces in charge of combating drug-
related crimes. Two levels of police units have a territorial scope: first, the district directorates 
(81 districts) and, second, the regional directorates (14 directorates). Finally, the third level is 
the National Drug Headquarters (NDH). Both the first and the second police units report data 
directly and independently from each other to the NDH.   
Thematic paper: Pilot study on wholesale drug prices in Europe 
53 
 
The National Drug Headquarters (NDH) compiles data on prices of different types of drugs, 
based on the information supplied by regional and district directorates. The system of 
collecting data on drug prices has been running in the Czech Republic (CZR) since 2002. 
Until 2008, these data was collected based on expert’s estimates and supplied by some 
districts and regional directorates. National drug prices were then published every 15 June 
and 15 January.  
In 2009, the system of price collection was improved and statistical analysis was introduced. 
In order to implement the new data collection mechanism, specific internal instructions were 
issued by the Police President, guaranteeing that the delivery of price information to the NDH 
became mandatory. Consequently, currently, each time that drug cases have data on prices 
this information has to be registered and sent to the NDH by e-mail (via an internal police 
network), in an Excel file. In case a police directorate does not have cases concerning all 
types of drugs, data reported will be based on expert’s estimates. Furthermore, if a police 
district detects a rapid change in the prices of a monitored drug (more than +/– 25 %), they 
are required to inform the central office immediately. Until now, no particular difficulties were 
detected in this operational system. A summary of these data is compiled and published in 
the NDH annual report. In this framework, the NDH annual report publishes wholesale drug 
prices statistics (average, mode and minimum–maximum range of wholesale drug prices) for 
each drug type.  
Improvements foreseen in the collection system in the near future 
As a follow-up to the first EMCDDA’s Expert meeting on wholesale drug prices organised in 
Lisbon (May 2009), the NDH and the Czech focal point (the Czech FP) have been developing 
a better system to collect WDP. Following these two years of experience, the Czech law 
enforcement entity has increased the priority given to this issue.  Special attention has been 
given to the availability of WDP data, its practices, the link between WDP and purity, patterns 
of construction of prices (pricing) from higher to lower levels in relation to purity and to the 
retail market. Consequently, there are improvements achieved in three main fields:    
1. The CZR started using the same definition of WDP as the EMCDDA — two years ago, the 
WDP definition depended on the drug related legislation. In the past, the terminology ‘larger 
extent’ was used, without being precisely defined. In this framework, cases of more than 1 kg 
or 1 000 tablets were regarded as ‘larger extent of drugs’ or ‘sale in bulk’.  
2. The Czech police forces organised and collected information to fill in the EMCDDA’s WDP 
template (with data concerning 2009) with the support of NDH — prices were reported in 
separate tables with information about the main type of drugs (herbal cannabis, cannabis 
resin, ecstasy, methamphetamine, opium, heroin, cocaine, LSD). Drug prices and 
correspondent seizures are split according to weight categories. The number of seizures with 
prices available is also reported by weight categories. Additionally, the NDH reports data on 
purity (for each weight category), whenever data exists. 
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Collected variables 
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3. More detailed qualitative data is now available, describing each case of large seizures.        
Further developments still required  
Outcomes from a thematic study in 2006 
In 2006, the Institute for Criminology and Social Prevention explored the difficulties in 
gathering seizures data. The study was published in 2008 and included a questionnaire 
survey answered by 168 experts with a professional background in criminal justice (judges, 
public prosecutors, officers of the NDH, customs officers and Prison Service officers). The 
questionnaire allowed officers from the NDH and Customs to comment on the difficulties of 
collecting seizures data. The pitfalls mentioned included: a drain in the experienced and 
trained staff consequent to the reduction of customs officers at the borders after the 
accession of the country to the Schengen Convention; the disclosure of investigation 
methods; the high level of organisation and extensive financial resources of drug traffickers; 
the insufficiency of drug enforcement legislation that could make drug-related cases more 
agile (e.g. the absence of the legal status of a chief witness); the fragmentation and poor 
interconnection of the information databases of cases under investigation between the 
individual branches of the police and the customs service; and corruption among Aliens and 
Border Police officers, civil servants, and judges. 
Small proportion of seizures containing larger volume of drugs 
Seizures data is collected by both the Police of the CZR (NDH) and by the General 
Directorate of Customs (Customs Drug Unit, CDU). Currently, the proportion of drug seizures 
containing more than 1 kg or 1 000 tablets observed in the CZR is relatively small. In 2007 
and in 2008, only 5 % of the number of seizures reported were above 1 kg or 1 000 tablets. In 
total, there were 68 seizures with volumes above 0.5 kg in 2009, representing 8 % of all the 
total seizures in that year. In 2009, seizures above 0.5 kg concerned herbal cannabis (45 
cases), cocaine (11), heroin (9), cannabis resin (2), and methamphetamine (1). However, 
information (estimations) concerning WDP per 1 kg (herbal cannabis (1), heroin (2)) was only 
mentioned in three of the aforementioned cases.    
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Difficulties faced in WDP data collection 
According to police officers, it is more difficult to obtain information about WDP than retail 
prices. It is easier to get information from the final customer than from the manufacturer or 
from the drug middleman or dealer from higher levels of the drug market. The police mainly 
use interrogation of arrestees and market price appreciation from experts as main methods to 
get WDP data.  
Drug purity data 
Drug purity data are obtained mainly from both the Forensic Science Institute in Prague (NDH 
sends samples of drug seizures to this institute) and the Customs lab (dealing with the 
seizures performed by CDU). The Czech FP gets all the data available every year. They also 
ask labs for more precise information on samples subject to purity analysis, in order to 
distinguish between wholesale and retail drug markets. Nowadays, the situation is better 
because NDH uses a special table (see above) where it is possible to compare information on 
purity and WDP received from forensic labs.      
Summary 
The CZR reports a lack of data on WDP because there are not many wholesale drug 
transactions detected and/or occurring. Consequently, this data collection process is 
particularly difficult. The proportion of large seizures (more than 1 kg) is small and concerns 
mainly brown heroin, cocaine and herbal cannabis. Following the European attention given to 
this subject, the Czech Republic has recently invested considerable resources and efforts 
aiming to improve the system of WDP data collection in institutions in charge of these 
activities. Results are to be expected in the near future. 
8.5. The German collecting procedures   
(Heiko Hergenhahn) 
Purity and price data  
There are three different sources of data on drugs purity in Germany. These sources are the 
Central Criminal Police Offices in the Federal States, the Federal Criminal Police Office (BKA) 
in Wiesbaden, and the Federal Financial Directorates as the supreme authorities for the main 
customs offices. All these authorities assess the active ingredient contents and cutting agents 
of drugs being seized by police or customs in Germany. The samples of seized drugs 
analysed are most often those involvingֹ ‘non-negligible’ quantities of drugs or are sent in as 
a request from the public prosecutor’s office. 
The definition of ‘non-negligible quantities of drugs’ is provided in the German Narcotics Act. 
The drug amounts were determined by the Federal Supreme Court, and their classification as 
‘non-negligible’ serves as basis for the indictment and support to courts’ decisions. In cases 
where the Federal Supreme Court has not taken any decision yet, this classification should 
provide guidance to other courts or toxicology experts. 
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Definition of ‘Non-negligible quantities’ of narcotic drugs in Germany 
Heroin: 1.5 g heroin-hcl — 150 units weighing 10 mg each; 30 extremely 
dangerous units weighing 50 g each  
Cocaine:              5 g cocaine-hcl — no competent ascertainment regarding units 
possible (various application forms) 
Amphetamine:   10 g amphetamine-base — 200 units weighing 50 mg each 
Methamphetamine:  5 g methamphetamine-base — 200 units weighing 25 mg each 
Ecstasy:   30 g base of MDMA, MDA, MDE (also MDEA) — 250 units weighing 
120 mg each 
Cannabis products:  7.5 g THC — 500 units weighing 15 mg each 
In cases of seizures made by police offices or customs authorities, the State Criminal Police 
Offices and the Financial Directorates report purity data to the BKA. These reports flow into 
the so called Statistical Programme on Narcotic Drugs (SAR) at the forensic science office, 
section toxicology at the BKA, just as the results of the analyses of samples from drug 
seizures made by the BKA itself. 
The SAR at the competent toxicology section in the BKA includes approximately 20 000 
individual results of forensic examinations carried out by the German laboratories each year. 
The median of the active ingredient contents is calculated for each type of drug. In connection 
with cannabis, a distinction is made between marijuana, hashish plants and hashish oil. 
The data is sent by the toxicology section to the competent section of the BKA to analyse the 
drug situation and to integrate it in the German annual drug report. The data include weight 
categories on street level (< 1 g), on mid-level (1–1 000 g) and on wholesale-level (1 000 g 
and more). There, is it possible to analyse data for different weight categories (such as 500 g 
to 1 500 g), at least for some types of drugs. It is also possible to calculate, for example, the 
arithmetical mean instead of the median of the active ingredient content. For the annual drug 
report, the BKA uses the median and the weight categories supplied by the 16 Germany State 
Criminal Police Offices. 
To obtain a picture of the scale of forensic records in the SAR, the number of records 
reported in 2008 by the police in the Federal States, by German customs and by the BKA 
itself are as follows: 
Collected forensic data of narcotic drugs (street-/mid-/wholesale-level) in 2008  
Herbal cannabis:  2 762 records 
Cannabis plants:  4 727 records 
Cannabis resin:   3 048 records 
Cannabis concentrate:  8 records 
Cocaine:   3 256 records 
Heroin:    4 364 records 
Amphetamine:   2 866 records 
Ecstasy:   541 727 tablets 
These reports are the basis for the calculation of the median drug purity content. 
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Wholesale-based heroin and cocaine purity is determined as follows. Since the purity level of 
heroin and cocaine preparations depends on the quantities seized, three weight categories 
were set to register active ingredient contents. One category comprises samples weighing up 
to less than 1 g, which represents ‘street-level trafficking’. The second category contains 
preparations with a weight of more than 1 g and up to 1 000 g. The third category comprises 
samples with more than 1,000 g, which represents the ‘wholesale trafficking’ of drugs. This 
complies with the classification used to register drug prices data. 
Since active ingredients are usually contained in drug preparations in the forms of base or 
salt, in order to better compare the results, the contents of psychotropic ingredients are 
referred to in base form, irrespective of the chemical form the additive substance actually 
presents in the illegal seized drugs. The validity could be further increased if the active 
ingredient content of a seized drug would be linked to its price. As in the case of the purity 
indicator, the BKA is able to show the development of drug-prices at street- and wholesale-
level over a certain period of time.  
Several problems exist to link both data sources in Germany: 
o In contrast to the drug prices gathered by police investigations, the information on active 
ingredient contents results only from the central analysis of the forensic results, based on 
samples built with drug seizures. 
o Price-related data refer invariably to cases that happened within the year concerned. 
Prices reported in the standard tables of the State Criminal Police Offices have to be sent 
to the BKA until 31 January of the following year. However, purity-related data refers to 
cases analysed in the concerned year. This means that in case of a seizure made in 
December 2008, its analysis will only be carried out in January 2009, influencing data 
concerning only the 2009 statistics. 
o The purity data include a high number of seizures made in some large or densely 
populated Federal States such as North Rhine-Westphalia, Bavaria, Lower Saxony, etc. in 
contrast to the scarcely populated Federal States with comparatively few seizure cases. 
To better understand this problem please take into account the German drug prices 
collection method: 
Annual reporting of drug prices in Germany 
The BKA receives annually price tables with summarised information of 16 German State 
Criminal Police Offices. 
These Federal States’ tables provide the following information: the minimum, the maximum 
and the typical prices of the main drugs, according to different weight categories (1 g, 1 000–
10 000 g, 10 000 g and more). Broadly speaking, the ‘typical price’ registered is in a sense 
similar to the mode. 
At the BKA, these ‘typical prices’ summed up and divided by the sum of the Federal States 
that have reported (principally 16), i.e. BKA calculates the mean of the prices provided by the 
16 German States Criminal Police Offices. 
That means that price-related data of the 16 State Criminal Police Offices are being taken in 
to account equally. In contrast to that, the development of purity data is decisively influenced 
by the data of the Federal States with more seizures made per year.  
Since there are different sources, which are similar (but not identical), as well as different 
methods used to collect both prices and purity, it is not possible to link data on purity to prices 
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on a one-to-one basis. Therefore the comparison of both indicators can only be made taking 
into account their average values. This problem exists not only on the wholesale-level but 
also to the street-trafficking level. 
Finally, it has to be mentioned that an assessment of the current drug situation is hardly 
possible on the basis of drug purity data and drug-price data.  
8.6. The Italian collecting procedures  
(Federico Quatrini) 
The Central Directorate for Antidrug Services (DCSA) is the Institution in charge of providing 
information on wholesale drug prices in Italy. As a law enforcement agency, the DCSA is 
under the competence of the Ministry of Interior. The DCSA’s main role is to centralise the 
information collected and provided by the regional Italian police forces from 12 provinces 
(Palermo, Reggio Calabria, Napoli, Bologna, Venezia, Firenze, Trieste, Roma, Torino, 
Genova, Milano and Verona). These 12 provinces are located in regions with the biggest drug 
markets, where the presence of organised crime and trafficking routes are notorious. These 
regional police forces report prices twice a year to the DCSA. This institution is in charge of 
compiling these data and estimating the minimum and maximum price for each drug type. 
Future developments 
Following the guidelines established by the EMCCDA, the DCSA has developed a project to 
optimise the wholesale drug prices collection system in Italy. The project is funded by the 
Italian Focal Point, and it will be a joint activity conducted by the focal point and the DCSA. 
The aim of this initiative is to improve the Italian data system on wholesale drug prices. In 
order to implement this goal, the DCSA will develop a template, which will be available to 
local police forces on an internet platform, to collect wholesale drug prices. This new template 
will collect information on WDPs, taking into account, among other characteristics: the 
methods used to collect WDP, transaction weights, and the overall information defined in the 
Project of wholesale drug prices launched by the EMCDDA. Concerning purity, this project 
intends to make a selective sample of purity tests, i.e. to require the purity testing of the most 
significant seizures. 
The Italian Wholesale Drug Price Project aims to develop a national Pilot study, which will be 
followed by a training exercise conducted by police officers at the DCSA in every Italian 
region. This training exercise will aim at developing regional skills that should allow local 
police officers to collect wholesale drug prices according to the pre-defined requirements.  
8.7. The Lithuanian collecting procedures  
(Aiste Bakasenaite) 
Since 2004, the Organised Crime Investigation 3rd Board of the Lithuanian Criminal Police 
Bureau has been the national coordinator, within national law enforcement agencies, in 
charge of compiling and analysing information regarding illegal drug trafficking in Lithuania. 
Consequently, every six months, the Lithuanian regional police divisions, the Customs 
criminal service and the State border guard service provide information on illegal drug 
markets to this Board. There are 10 regional police divisions with organised crime 
investigation services that send detailed reports on illegal drug markets. These reports 
include information on retail and wholesales drug prices in Lithuania.   
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Price information  
Regional police divisions provide information complying with the following template (it is 
mandatory to fill in all the columns of the table): 
Prices of narcotic and psychotropic substances — template of regional police divisions 
Date of 
information 
received 
 
Name of 
the 
substance 
Total 
quantity of 
the 
substance 
(1) 
Price of 
the 
indicated 
quantity 
(2) 
(currency 
unit) 
Source of  
information 
(3) 
Region Identified 
purity 
Retail/wholesale 
(4) 
(additional 
information) 
 
        
        
1. Total quantity of the substance — to indicate the total quantity.  
2. Price of the indicated quantity — to indicate the value of the total quantity. 
3. Sources of information: 
1- purchases ( information received from undercover agents, investigating operational case, etc.). 
2- use of technical measures (for example — wiretapping). 
3- informer. 
4- interrogation of a detainee. 
5 –public source (press, anonymous information.) 
6- other. 
4. Retail/wholesale — to indicate prices of other transaction volumes. For instance, when reported prices 
concern 1 g transaction (sometimes officers use this as an indicator of prices in wholesale markets).  
 
In order to make a clear distinction between different market layers, minimum thresholds have 
been defined for wholesale transactions, middle market and retail transactions. When the total 
quantity traded is below 50 grams (50 tablets), prices are classified as retail. Drug 
transactions between 50 grams and 1 000 grams are classified as middle market 
transactions. Prices of transactions above 1 000 grams are accounted as wholesales prices. 
The Board uses a standard methodology to calculate the average wholesales drug prices 
(and retail prices). 
Concerning the sources of drug prices data, information provided by hidden purchases and by 
other technical methods (for example, by wiretapping) are the most valuable. In case these 
methods do not provide price information, other sources are taken into account. In this case, 
average prices are marked as ‘intelligence information’. 
The Board summarises and analyses information on drug prices. This information is then 
used to prepare the Annual Report of Illicit Drugs Trafficking and Their Control in Lithuania. 
The Board provides this information, aiming at answering to requirement of the Government 
of the Republic of Lithuania and contributing to the draft of the National programme for control 
of drugs and prevention of drug addiction. The Board also provides this information to Europol 
and other international organizations. Last but not least, average drug prices are also 
provided to Lithuanian police officers.  
The main difficulty faced by the Board when calculating national wholesale drug prices is the 
rarity of information provided by reliable sources, such as hidden purchases. 
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Purity information 
Since 2008, Lithuania has been collecting information on drugs purity in relation to drug 
prices. This is especially the case when the method of drug purchases is used. In this case, it 
is asked to indicate the level of purity and to relate it to the price level. However, 2008 data 
shows that there is not enough information to build a reliable purity adjusted prices database 
at the wholesale level. The Board has mostly received information concerning retail prices 
and the purity of small quantities.  
Foreseen developments  
An electronic system has been developed recently to collect information about detentions or 
undertaken investigations regarding illegal drug circulation in Lithuania. Law enforcement 
officers from regional police divisions have to fill in detailed information in electronic format 
concerning detentions and investigations and to send these files to the 3rd Board. These 
electronic templates include questions about drug prices. Consequently, the Lithuanian 
Criminal Police Bureau expects that price information will become more reliable in the future, 
since it will be directly related to concrete cases. This information will be used to perform and 
report drug prices analysis.  
8.8. The Portuguese collecting procedures  
(Carla Ribeiro and Catarina Guerreiro) 
Institutions in charge of collecting wholesale drug prices and purity  
In Portugal, the Criminal Police (PJ) is the law enforcement body in charge of providing 
information and analysing the trafficking of narcotic and psychotropic substances. This 
Institution centralises information on drug trafficking, collected by those law enforcement 
agencies which participate in Joint Intervention and Coordination Units. The law enforcement 
agents working in the field are members of the PJ, the National Republican Guard (GNR), the 
Public Security Police (PSP), the Foreign Nationals and Borders Service (SEF), the 
Portuguese Board of Customs (DGAIEC) and other public bodies, such as the General 
Directorate for Prisons (DGSP) and Maritime Police (PM), with competence in the control, 
monitoring and prevention of drug trafficking. These law enforcement agencies collect 
information on drugs prices and, in particular, of WDP.  
This information is gathered and centralised by the PJ, which is in charge of compiling, 
analysing and disseminating these data, taking into account the needs of the target audience. 
The Institute on Drugs and Drug Addiction (IDT, IP) is also a receiver of this information. The 
IDT itself is also in charge of analysing this information and disseminating it, in the context of 
the different national and international commitments. 
Concerning the information on drugs purity, the PJ is also the main entity involved, with the 
cooperation of the Portuguese Laboratory of Forensic Science. The PLFS collects, 
processes, and records traces and performs tests in different fields of forensic science, 
including toxicology. Therefore, information on the purity of drugs at different levels of the 
drugs market is regularly collected. 
Methods used to collect price information  
The most common method used to collect wholesale drug prices is the interrogation of 
arrestees, directly linked to cases of drug seizures. For many years, the information on WDP 
has been gathered through a questionnaire that is to be filled in by police officers each time 
Thematic paper: Pilot study on wholesale drug prices in Europe 
61 
the seizure of drugs, goods, values and documents occurs. This questionnaire should also be 
filled in when there were individuals identified (through evidence) as being possible drug 
traffickers or involved in either trafficking or use, independently of whether they had been 
detained or not. 
Through these instruments — Forms TCD Model A on substances and Model B on the actors 
— diverse information has been gathered, including that on prices of the drugs seized and of 
the total volume of each seizure. This information has been filled in by the different law 
enforcement agencies and centralised by the PJ, incorporating the Integrated Criminal 
Information (SIIC). 
Information on wholesale drug prices is also collected during criminal investigations, in 
particular through informants, documentation seized, operational intelligence material and 
evidence prosecution papers. The record of this information only indicates reference prices, 
more precisely ‘typical’ values, and it does occur less frequently. 
Methods used to collect purity information 
The PJ Forensic Laboratory regularly undertakes tests to identify and determine the purity of 
seized drugs at different levels of the market. This information is registered, made available 
and updated at a centralised level. 
Reporting procedures 
Currently, Portuguese institutions do not report data on WDP as defined in this Pilot study. 
The data analysed and reported by the PJ and the IDT, IP to the national and international 
fora refers usually to the average prices of drugs seized, according to the trafficking and 
trafficking-use cases. This information integrates price records related to the seizures of 
quantities inferior to those set in this Pilot study to WDP. However, the currently available 
procedures of collecting and recording price data do provide the required information on 
WDP, in line with the standards set by this Pilot study.  
Portugal has been reporting data on drug prices since 2005 (although data has to be 
interpreted cautiously due to the small volume of data available for some years). 
Consequently, and taking this constraint into account, it should be possible to provide 
wholesale drug prices in the future, measured with the common statistical indicators. 
Concerning purity, it has not been the practice to report data on the purity of drugs seized in 
the wholesale market as defined in this project. This data is usually produced in the context of 
criminal investigations and of investigations of criminal proceedings, being only occasionally 
reported for other purposes. However, the methods that are currently in place to collect and 
record this type of data can in the future be used to provide information in accordance with 
the required in the current WDP project. 
Data limitations 
The small number of incidents where drug price/purity data is collected every year is the 
major constraint of the report on wholesale drug prices and purity. This limited volume of 
information available may not guarantee representativeness and reliability of the wholesale 
drug price information, to be provided in the future. 
Under this Pilot study, the IDT and the IP analysed WDP data available for the last five years 
(2005–09). They concluded that the greatest volume of records on WDP referred to cannabis 
resin, with about 10 records for each year (minimum = 5, maximum = 14). This figure 
represented, however, only about 10 % of the total number of seizures recorded with volumes 
equals or above 1 kg (1 000 units). Concerning other drugs (herbal cannabis, heroin, cocaine 
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and ecstasy), there were only a few WDP registers a year (1–2 cases). The number of 
registers varied a lot depending on the number of seizures. For example, in 2008, there were 
nine seizures of heroin, four of ecstasy and 151 of cocaine, within the defined volumes of 
transactions, with price information. 
The small number of records of WDP is not easily surmountable, as many arrestees are only 
drug courriers, according to information gathered by criminal investigation, being paid 
according to the transport and not directly to volumes of transported drugs. 
As for the purity of drugs, the volume of data records will ultimately depend on the number of 
seizures involving amounts bigger then 1 kg or 1 000 units and on the optimisation of the ratio 
of drug testing/wholesale seizures. 
Availability of statistics 
If the number of WDP records is large enough, Portugal can provide information on the 
statistical measures required in this phase of the project (minimum and maximum values, 
mean and median). Over the last years, the small number of WDP records available made 
impossible the compilation of statistical measures for every drug but cannabis resin. For other 
drugs, as herbal cannabis, heroin, cocaine and ecstasy, only the minimum and maximum 
WDP can be provided. Information on ‘typical’ prices as a complement to traditional statistical 
values is also available. It is also possible to provide information on purity of seized drugs, 
crossing this information with WDP. 
Main strengths and weaknesses of data collection procedures 
As already mentioned, the main weakness of the procedures for collecting data on WDP in 
Portugal is the small volume of WDP data available for most substances, which is largely due 
to exogenous factors and, thus, difficult to overcome. 
One of the main strengths of the Portuguese collecting system is the fact that it has been in 
place for a long time. Consequently, there is some experience of gathering this information 
(prices of drugs seized at different levels in the distribution chain of trafficking and trafficking 
use), and consequently it is possible to provide additional information, which allows to 
contextualise the WDP database. 
Another important point is that the information gathered by all law enforcement bodies is 
centralised by the PJ and regularly made available to IDT, IP, to the national focal point, and 
is then easily available to the EMCDDA. 
Additionally, the systematic recording of purity tests to identify and determine the purity of 
seized drugs at different levels of the market is done within the same agency that centralises 
WDP information (Laboratory of Forensic Laboratory of the PJ). This is a strong advantage of 
the system, allowing to easily relate data on WDP and their purity. It should be possible to 
build purity-adjusted prices. 
Last but not least, the need to optimise data on supply reduction, particularly on the purity of 
drugs, is inscribed as a national priority in the 2009–12 Action Plan. This optimisation may all 
ready consider the information needed for this project. 
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8.9. The Slovak collecting procedures  
(Ivana Buckova)  
Background information 
Gathering intelligence information concerning available drugs in the Slovak drug scene is 
carried out during the activity of monitoring drug markets. More specifically, it is part of the 
Slovak law enforcement activity to gather intelligence information on drug markets while 
investigating offenders.  
This activity provides statistical information about the volumes and types of drug seized, 
characteristics of drug-related offenders (e.g. age, education, employment status), modus 
operandi, purity of drugs seized, typical additives and precursors (on the basis of forensic 
analysis) and drug prices.  
Collection of price data 
There are two main types of Slovak police officers who collect information on drug prices. 
First, those from the National Drug Service (the Bureau of the Fight Against Organised Crime 
of the Police Force Headquarters) and from the regional anti-drug departments (the Bureau of 
the Fight Against Organised Crime of the Police Force Headquarters) and its investigation 
department. Secondly, those officers belonging to the Customs Directorate of the Slovak 
Republic. Additionally, there are institutions such as Europol which also provides price 
information. 
The collected information is then reported to the Slovak national focal point, Europol, 
UNODC, and other organisations. 
Information on drug prices is compiled every three months with the use of a specific template. 
On the basis of this data collection process within the Slovak law enforcement centres, we are 
able to: quarterly collect and compare intelligence on drug prices in Bratislava and eastern, 
central and western Slovak regions; define minimum and maximum drug prices for regions 
during certain time periods (e.g. in September 2009, in the region of western Slovakia) and; 
define minimum and maximum drug prices during the year for the annual reports.  
In case a new sort of drug is discovered or if there is a rapid change in drug prices, police 
officers are due to inform the central Bureau immediately. In this case, custom services are 
informed, and adequate measures are implemented.  
In the Slovak Republic, the main constraint is to report information complying with the 
definition of wholesale quantities of drugs traded. The volumes most frequently seized vary 
from drug to drug. Cannabis seizures are frequently above 1 kg, but when it comes to 
methamphetamine, ‘cooks’ prepare only smaller volumes of it, close to 1 kg. Since 
methamphetamine has to be consumed during the three days after manufacturing, it tends to 
be commercialized in small portions to prevent quality decreases. In this country, the typical 
volumes seized of heroin and cocaine varies between 30 grams to 100 grams, despite the 
fact that the Slovak Republic is also a transit country for this trafficking.   
According to Slovak Penal Code, penalties applied to offenders depend on the value of the 
drugs seized. If the value of seized drugs is higher than EUR 2 665, the penalty is normally 
imprisonment, which may vary between 5 to 10 years. One of the main problems that occur in 
trial is the authentication of drug prices.  
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Collection of purity data 
In the Slovak Republic, every suspicious substance seized by police is analysed by the 
forensic laboratory. The objective of these analyses is to determine the type, the quantity and 
the concentration of the active substance (i.e. purity). Based on the relation between purity 
and weight, it is estimated the amount of doses which would be possible to sell, as a 
consequence of trafficking. According to the quantity of doses estimated, there are two legally 
binding procedures foreseen. If the number of estimated doses is below 10, drugs are 
considered as being destined to own consumption, and neither the purity nor prices are 
registered. In case the number of doses exceeds 10, then, the price, the purity and the 
number of estimated doses are registered. This information is prepared to support a 
‘Suggestion of indictment’ to be sent to court. This document should be presented in court 
and contribute for the trial. However, there is not an established procedure of compiling and 
making statistical data analysis of this information, currently. 
8.10. The Spanish collecting procedures  
(Alicia Peláez Santiago )  
Institutions in charge of collecting data on wholesale drug prices and purity  
In Spain data on drug prices and drug purity are collected by different Institutions. Drug 
prices data are collected by the Oficina Nacional de Estupefacientes (OCNE). This is a law 
enforcement agency under the responsibility of the Spanish Home Affairs. Information about 
wholesale drug prices (WDP) is usually compiled in the course of regular drug investigations. 
The methods most often used to collect WDP information are interrogation of arrestees, 
inquiring convicted prisoners and suspects of drug dealing and, less frequently, information 
captured by informants and wire tapping procedures.   
Information concerning drugs purity is obtained through sample analysis, reported by the 
laboratories of the General Direction of Pharmacy (Dirección General de Farmacia) or other 
regional institutions in charge, which answer to the Health Ministry. These reports are then 
communicated to law enforcement agencies and to the judicial authorities.  
In Spain, there are different types of sanctions according the type of crime committed. In 
order to estimate the value of the financial penalties associated with drug trafficking, it is 
necessary to estimate the final value of the seized drug (Article 377 of the Penal Code — 
L.O. 10/1995). To comply with the principle of equal rights, the same price shall be applied 
across the country, except in the case where the actual price of the transaction is known. For 
this reason, the OCNE is the institution in charge of determining drug prices. 
Drug prices are collected by units of the National Police force and by the Guardia Civil from 
each Spanish Region, more specifically, by the Investigation and the Crime Prevention Units 
(Grupos de Investigación de Estupefacientes y Unidades de Seguridad Ciudadana). These 
units, due to their daily contact with retail traffickers and expertise in combating drug 
trafficking, follow drugs prices evolution and trends closely. The information collected in each 
drug squad is send to the respective regional police station (Jefaturas Superiores de Policía 
y Zonas de la Guardia Civil). Regional units are in charge of calculating simple averages of 
the information collected and of sending this information to the OCNE. The OCNE centralises 
and summarises the received information. Subsequently, it estimates the national average 
and disseminates it (this value is a simple average that excludes extreme values). This 
information is then published each semester, in January and July of each year.  
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Publishing policy  
Based on the data produced by OCNE, the Spanish Intelligence Centre against Organized 
Crime (CICO) periodically produces reports and studies about the evolutions of drugs prices 
and purity, seized at the level of a dose, a gram or a kilo of drugs.  
Information on the purity of drugs allows to assess drug toxicity and its public burden. 
Consequently, this information is used to determine penalties of drug trafficking. 
Furthermore, purity levels are also indicators of drugs supply and demand, having also an 
impact on drugs prices.  More specifically, CICO uses drugs purity information combined with 
drugs prices for different levels of drugs markets (retail, mid-market and wholesale markets). 
In order to analyse this information, a statistical analysis is performed for each market level, 
analysing possible correlations and market trends. 
8.11. The Turkish collecting procedures  
(Ali Ünlü) 
In Turkey, law enforcement squads working in the drugs field compile information on 
wholesale drug prices. To this end, drug prices are queried and the resulting information 
compiled through structured forms and submitted to Turkish Monitoring Centre for Drugs and 
Drugs Addiction (TUBIM) every six months. Furthermore, drug prices reported by suspects 
interrogated during drug interceptions and prices identified through covert operations are also 
reported to the Department of Anti-Smuggling and Organised Crime (KOM), under which the 
National Focal point also operates.  
Concerning drugs purity, data are provided by the National Forensic Laboratories and 
centralised by the Turkish Monitoring Centre for Drugs and Drugs Addiction (TUBIM) every 
six months. Drug purity results are based on the seizures made by law enforcement units.  
However, price data for 2009 does not specifically distinguish between wholesale transactions 
(as defined according to pre-defined volume thresholds) or smaller transactions. The same is 
true concerning the level of purity reported. Until now, it has not been possible to clearly 
distinguish between the levels of purity associated with different volumes of drugs traded. 
Consequently, the data reported in this Pilot study are based on undistinguished volumes of 
drugs traded, as reported by local law enforcements in 2009. 
Future developments 
A workshop with law enforcement representatives at local level and forensic laboratory 
experts is foreseen to take place in order to introduce the new wholesale drug price and purity 
data collection requirements to local police officers.  
8.12. The UK collecting procedures   
(Tony Saggers) 
Introduction  
The Expert Evidence department, within the Serious Organised Crime Agency, maintains the 
responsibility to collate and disseminate final data regarding UK ‘street level’ (retail), ‘mid-
market’ and ‘wholesale’ drug prices. This is achieved upon various platforms and interactions 
within SOCA and with law enforcement partners.  
Although SOCA retains the lead with particular regard to wholesale prices, interactions are 
conducted throughout the year with partners who also contribute data with regard to the 
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domestic wholesale markets within England, Scotland, Wales, Northern Ireland, Jersey, 
Guernsey and the Isle of Man.  
The data are supplied to SOCA, via various channels and liaisons, and ultimately coordinated 
for publication within a ‘restricted’ distribution. These data are also utilised for various other 
purposes, such as evidential valuations and interpretations, operational and deployment 
strategies and briefings, intelligence assessments, specialist staff training, press releases, 
responses to parliamentary questions, political reporting and drug market assessments. 
These data are also utilised to respond to the United Nations annual questionnaire and within 
aspects of the UK Threat Assessment.  
Contributors  
WDP are collected from 38 polices services in England, four police services in Wales, eight 
police services in Scotland and the police services for Northern Ireland, Jersey, Guernsey and 
the Isle of Man. They feed price data to SOCA from their own varying collection methods on 
an informal but regular basis via practitioners, more formal quarterly updates (from some 
regions) and on an annual basis through the completion of a collection table instigated by 
SOCA. It should be noted there is no standardised approach to the initial recovery of price 
data, although there is a standard reporting criteria to SOCA.  
Prices are collected and monitored for various unit sizes depending upon the commodity and 
how it is commonly traded. These unit weights combine metric and imperial measures as both 
co-exist within UK domestic drug markets. At wholesale, however, a kilogram is the common 
traded unit for all solid/powder commodities. Units of  
1 000 are recognised with regard to wholesale prices tablets and other substances supplied 
by the item rather than weight.   
SOCA monitors WDP throughout the year from evidential recoveries (such as documents and 
lists compiled by traffickers), insight and interpretation of covertly recorded conversations, the 
use and deployment of human intelligence sources such as informants and undercover 
officers, interviews with detained traffickers and market interpretation based upon wider 
intelligence monitoring. SOCA also maintains international liaison with regard to 
understanding WDP impacting upon importation activity into the UK.  
Collection scope and methods  
Until 2006, there was an emphasis to supply a single figure to best represent the price of a 
drug in an area or particular town or city. Although this figure was referred to as the ‘average’, 
there was no statistical foundation for the sum involved. This figure actually represented a 
more practical ‘typical’ price; that being most commonly encountered. The current collection 
methodology changed this process in 2006 to ensure a more informative perspective and to 
generate data that wholly reflected the reality of drug markets. 
The current collection process requests contributors to provide the following: 
• the common range of prices (not including extreme anomalies) 
• the most commonly encountered (or typical) price within this range.  
From the data collected SOCA is then able to demonstrate the UK range (excluding the 
extremes), the average, and the mode of the ‘most commonly encountered prices’.  
SOCA achieves a central contribution through internal liaison between various departments 
exposed to price data through intelligence, operational and evidential encounters, and this is 
complimented by the contributions from the 53 police services. As at 2009, price data was 
being reported from 123 towns and cities in addition to the information being collected by 
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SOCA regarding national and international activity impacting upon the UK. With particular 
regard to WDP, each police service was able to provide kilogram prices for at least four of the 
common commodities being supplied within their area.  
Wholesale drug prices are currently available for the following commodities at kilogram or 
1 000 units: cocaine, heroin, opium, ecstasy tablets, MDMA powder, Ketamine, amphetamine, 
cannabis resin, herbal cannabis and skunk cannabis. Prices for the cutting agents 
Benzocaine, Phenacetin, Lidocaine are also available. Insufficient data at kilogram/1 000 
units is currently available for: crack cocaine (commonly sold in ‘ounce’ weights at wholesale), 
and LSD (very limited wholesale price insight),  
Data verification 
SOCA does not request verification from police service contributions regarding the number of 
incidents or sources of data. Data submitted are, however, assessed for credibility and if 
found not to reflect the wider picture, at that time, an enquiry would be conducted with the 
contributor to explain and justify the prices.  
SOCA does not record the number of incidents leading to SOCA-based WDP collections. 
Within the UK, many drug price revelations are not directly associated to drug seizures as the 
sources utilised provide insight from past, current and future criminality. 
The expert evidence department is responsible for assessing evidential audio material and 
recovered documents that are linked to criminal conspiracies and drug seizures. Some of 
these incidents provide direct insight of drug prices that are relevant to specific drug seizures. 
Wholesale drug seizures are subjected to forensic analysis including tests for purity and, on 
occasions, potency (THC for cannabis). 
The SOCA WDP database establishes credible price ranges and identifies common prices 
within these ranges. This is agreed by a selected group of practitioners and managers 
conducting roles within departments who encounter drug prices. Anomalies outside of the 
credible range are monitored to assess whether new trends are emerging or whether either 
end of the range needs to be extended or shortened within the next formal reporting.  
The final output is not wholly statistical as (explained above) the data set is not accurately 
quantifiable. The accuracy of the data produced, however, is confidently claimed to be 
practically representative of the prices being commanded and paid by drug traffickers within 
the UK. 
‘Price adjusted for purity’ can be conducted for cocaine and heroin, in particular, although this 
is only done with regard to market assessments as it is accepted that within the criminal 
world, purity is often not known and prices tend to be negotiated in line with ‘perceptions of 
quality’ based upon influences such as reputation, association, trading dynamics, appearance 
of quality, crude testing methods and the trading environments/locations.  
Conclusion  
Within the UK, awareness of WDP is considered to be well informed and, as such, expert 
witnesses utilise this data to inform criminal court trials and proceeds of crime hearings. 
Questions regarding WDPs and markets from the EMCDDA, Members of Parliament, 
government departments, researchers and senior managers within law enforcement are 
responded to with confidence that the data is ‘timely’ and ‘representative’. 
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9. Conclusions 
The Pilot study on wholesale drug markets aims to contribute to the development of the 
European indicators on drug markets in Europe. In this framework it describes the ‘State of 
the Art’, concerning the information and data on wholesale drug prices in Europe. 
Furthermore, it also presents a set of templates designed to collect wholesale drug prices in 
European countries, as agreed by national law enforcement officials and Europol, for the 
purpose of the Pilot study,  i.e. by the main entities in charge of implementing the regular day-
to-day data collection exercise among international data users. These questionnaires are also 
designed to answer to the main requirements of the analysis of wholesale drug prices, from 
the perspective of policy makers or researchers. In order to test the designed questionnaires, 
two rounds of data collection took place, involving real data from 2008 and 2009. 
This Pilot study is the result of work developed for more than two years, with the voluntary 
cooperation of the Reitox network, national experts of national law enforcement agencies — 
with special emphasis given to the Serious Organised Crime Agency (SOCA), Europol and 
the EMCDDA.  
The main conclusions of this work are as follows: 
1. It is feasible to collect wholesale drug prices in Europe, with a sufficient or even good 
degree of quality in a large number of countries; although in some other countries 
data collection and compiling procedures still show some room for improvement. 
Additionally, it is also possible in a large number of countries to collect underlying 
wholesale purity; 
2. There is a consensual approach amongst the participants in the Pilot study towards 
the definition of wholesale drug prices and purity and of the main information required 
to compile to provide data. There was also consensus about the investigation 
methods used to collect this information attained in illegal transactions, as well as the 
methods that should be used to compile this information and to treat it statistically; 
3. Out of the 24 European countries that replied, 23 collect wholesale drug prices. 
Furthermore, 18 countries did participate in the voluntary and testing data collection 
rounds, providing real data for 2008 and/or 2009. This study also provides a very 
detailed description of 12 national data collection systems and operational 
arrangements in place used to report WDP and purity; 
4. The volume of available information on wholesale drugs varies considerably from 
drug to drug and from country to country. This study provides templates to collect 
wholesale drug prices aiming to accommodate the requirements of different countries 
in the field of WDP collection and data analysis; guaranteeing that the underlying 
procedures are clear when data are reported;  
5. There is political momentum at European and national level that supports the 
implementation of this data collection system as a routine procedure, coordinated by 
the EMCDDA; 
6. A significant numbers of countries have already started changing their national 
procedures in order to accommodate the results of this Pilot study. A large number of 
countries have reported changes in their procedures in order to comply with the 
EMCDDA requirements and templates. As a consequence of the work of the expert 
group on wholesale drug prices, 10 countries revised or have set plans to revise their 
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internal law enforcement practices, in order to comply with this price data collecting 
system. In Germany, the BKA arrived to an agreement with the 16 Federal States 
offices to adapt their price reporting and collecting procedures.  In France, the Office 
Central pour la Repression du Trafique des Stupéfiants (OCRTIS) has linked 
wholesale drug prices to purity. In Austria, the Criminal Intelligence Service, MOI, has 
improved the Internet-based application (which links local police stations to the 
central police office) with the objective of relating purity to prices. In the Czech 
Republic, the national focal point has made an agreement with national law 
enforcement to relate wholesale drug prices to purity. In Belgium, prices have been 
related to the size of the underlying transactions or seizures, depending on the 
source of the information. In Italy, Lithuania and Turkey training is already planned for 
law enforcement agents. In Cyprus and Hungary, national law enforcement offices 
are waiting for the final wholesale drug prices questionnaire to adjust national 
procedures accordingly. 
7. A preliminary analysis of the data reported seems to suggest that the wholesale drug 
prices data reported is consistent to that systematically reported to the EMCDDA 
through the retail drug prices data collection system, confirming that the 
methodologies used in both databases are complementary.  
8. Finally, the discussion entailed in this study by European experts on wholesale drug 
markets and prices, and the results attained during this study suggest that the 
EMCDDA can soon implement a systematic collection of wholesale drug prices in 
Europe. Although the level of detail of the data collected might vary within European 
countries at an early stage, there is a core of countries that are ready and willing to 
implement this data collection mechanism in the short run. Taking also into account 
that this process has been fully sustained by Europol, the EMCDDA has a privileged 
position to provide a more complete picture of the European drug markets. The 
EMCDDA is now ready to build on the work developed in the last 15 years in the area 
of retail drug markets, and start providing information on wholesale drug markets. 
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Annex 1 — General questionnaire on wholesale drug prices 
collection mechanism 
  
 
 
 
QUESTIONNAIRE ON 
WHOLESALE DRUG PRICES COLLECTION MECHANISM 
TO BE COMPLETED BEFORE 30  APRIL 2009 
 
Country          Institution       
1- Does your country collect wholesale drug prices (19) (WDP) for those drugs detailed 
below (Table 1). If yes: 
1. Please mark the first column.  
2. Since when does your country collect these prices (column 2)? 
3. With which periodicity (column 3)? 
2- In case your country does not publish these data, do you think it will be possible to 
collect and publish these prices in the near future with a reasonable effort (column 4)?  
Table 1 — Collection of wholesale drug prices 
 
(1) 
Collects WDP 
(2) 
Starting Year 
(3) 
Periodicity 
(4) 
Possible to publish 
WDP in the near 
future? 
Cannabis resin   Yearly Possible 
Herbal cannabis   Yearly Possible 
Cocaine   Yearly Possible 
Heroin brown   Yearly Possible 
Amphetamines   Yearly Possible 
Ecstasy   Yearly Possible 
LSD   Yearly Possible 
3- In case your country does not strictly comply with the suggested definition of 
wholesale drug prices, does your country use an alternative definition? If yes, describe 
it briefly, please.  
Table 2 — Alternative definitions to wholesale drug prices 
Cannabis resin 
 
Herbal cannabis 
 
Cocaine 
 
Heroin brown 
 
Amphetamines 
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Ecstasy 
 
LSD 
 
 
4- Can the wholesale drug prices series existing in your country be disclosed to the 
EMCDDA and published? Yes 
  
5- What are the methods used in your country to collect wholesale drug prices? 
Table 3. Methods used to collect wholesale drug prices 
 Frequently Seldom Never 
Drug purchases 
  
 
Informants 
  
 
Interrogation of arrestees    
Wire-tapper registers and other covertly 
obtained audio material 
   
Market price appreciation from experts (police 
and academic)    
Documentation seized by law enforcement    
International cooperation 
  
 
Operational intelligence material 
  
 
Prosecution evidence papers/case files    
Social surveys and drug user counselling    
Academic surveys    
 
6- Can you report minimum and maximum WDP prices, means, modes and or medians? 
In case you cannot, can you report typical WDP? 
Table 4 — Collection of wholesale drug prices 
 
Minimum and 
Maximum 
Mean Mode Median Typical 
Cannabis resin      
Herbal cannabis      
Cocaine      
Heroin brown      
Amphetamines      
Ecstasy      
LSD      
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7- Do you have regional wholesale drug prices? Yes If yes, can you report them? Yes 
 
8- Can you relate this data to purity/potency data? Yes 
 
Comments       
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Annex 2 — Results of the general questionnaire on wholesale 
drug prices collection mechanism 
Table 1 — Collection of wholesale drug prices 
 Collects WDP 
  
Cannabis 
resin 
Herbal 
cannabis Cocaine 
Heroin 
brown Amphetamines Ecstasy LSD 
BE         
CZ 
       
DK 
       
DE 
       
EE 
       
IE 
       
ES 
       
FR 
       
IT 
       
CY 
       
LT 
       
HU 
       
NL 
       
AT 
       
PL 
       
PT 
       
RO 
       
SI 
       
SK 
       
FI 
       
SE 
       
UK        
HR        
TR 
       
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Table 2 — Starting year of wholesale drug prices data collection 
 
Starting year 
  
Cannabis 
resin 
Herbal 
cannabis Cocaine 
Heroin 
brown Amphetamines Ecstasy LSD 
BE 2005 2005 2005 2005 2005 2005   
CZ 2002 2002 2002 2002 2002 2002 2002 
DK 1985 - 1985 1985 1985 1985 - 
DE 1975 1975 1983 1975 1993 1996 1996 
EE 
- - - - - - - 
IE 
- - - - - - - 
ES 1995 1995 1995 1995 1995 1995 1995 
FR 2000 2000 2000 2000   2000   
IT 2002 2002 2002 2002 2002 2002 2002 
CY 2004 2004 2004 2004 2004 2004 2004 
LT 2004 2004 2004 2004 2004 2004 - 
HU 
- - - - - - - 
NL 2005 2005 2005 2005 2005 2005 2005 
AT 1999 1999 1999 1999 1999 1999 1999 
PL 
- - - - - - - 
PT 2009 - 2009 2009 - 2009 - 
RO 
- - - - - - - 
SI 2004 2004 2004 2004 2004 2004 2004 
SK 1995 1995 2000 2000 2000 2000 2000 
FI 2002 2002 2002 2002 2002 2002 2002 
SE 2010 2010 2010 2010 2010 2010 - 
UK 2000 2000 2000 2000 2000 2000 2000 
TR 2007 2007 2007 2007 2007 2007 2007 
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Table 3 — Periodicity of wholesale drug prices data collection 
 
 
Periodicity 
  
Cannabis 
resin 
Herbal 
cannabis Cocaine 
Heroin 
brown Amphetamines Ecstasy LSD 
BE Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
CZ twice/year twice/year twice/year twice/year twice/year twice/year twice/year 
DK Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
DE Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
EE Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
IE Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
ES twice/year twice/year twice/year twice/year twice/year twice/year twice/year 
FR yearly yearly yearly yearly yearly yearly yearly 
IT twice/year twice/year twice/year twice/year twice/year twice/year twice/year 
CY Quarterly Quarterly Quarterly Quarterly Quarterly Quarterly Quarterly 
LT twice/year twice/year twice/year twice/year twice/year twice/year Other 
HU Other Other Other Other Other Other Other 
NL Quarterly Quarterly Quarterly Quarterly Quarterly Quarterly Quarterly 
AT Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
PL Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
PT Yearly Other Yearly Yearly Other Yearly Other 
RO Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
SI Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
SK Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
FI Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
SE twice/year twice/year twice/year twice/year twice/year twice/year Other 
UK Quarterly Quarterly Monthly Monthly Quarterly Quarterly twice/year 
HR Yearly Yearly Yearly Yearly Yearly Yearly Yearly 
TR twice/year twice/year twice/year twice/year twice/year twice/year twice/year 
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Table 4 — Possibility of publishing wholesale drug prices data in the near future 
 
  
Possible to publish WDP in the near future? 
  
Cannabis 
resin 
Herbal 
cannabis Cocaine 
Heroin 
brown Amphetamines Ecstasy LSD 
BE Possible Possible Possible Possible Possible Possible Very difficult 
CZ Possible Possible Possible Possible Possible Possible Possible 
DK Possible Possible Possible Possible Possible Possible Possible 
DE Possible Possible Possible Possible Possible Possible Possible 
EE Difficult Difficult Difficult Difficult Difficult Difficult Difficult 
IE Difficult Difficult Difficult Difficult Difficult Difficult Difficult 
ES Possible Possible Possible Possible Possible Possible Possible 
FR Possible Possible Possible Possible Very difficult Possible Very difficult 
IT Possible Possible Possible Possible Possible Possible Possible 
CY Possible Possible Possible Possible Possible Possible Possible 
LT Possible Possible Possible Possible Possible Possible Very difficult 
HU Difficult Difficult Difficult Difficult Difficult Difficult Difficult 
NL Difficult Possible Possible Possible Possible Possible Difficult 
AT Possible Possible Possible Possible Possible Possible Possible 
PL Difficult Difficult Difficult Difficult Difficult Difficult Difficult 
PT Possible Very difficult Possible Possible Very difficult Possible Very difficult 
RO Possible Possible Possible Possible Possible Possible Possible 
SI Possible Possible Possible Possible Possible Possible Possible 
SK Possible Possible Possible Possible Possible Possible Possible 
FI Possible Possible Possible Very difficult Possible Possible Very difficult 
SE Possible Possible Possible Possible Possible Possible Very difficult 
UK Possible Possible Possible Possible Possible Possible Possible 
HR Possible Possible Possible Possible Possible Possible Possible 
TR Possible Possible Possible Possible Possible Possible Possible 
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Table 5 – Alternative definitions to wholesale drug prices 
 
  Cannabis resin Herbal cannabis Cocaine Heroin brown Amphetamines Ecstasy LSD 
BE        
CZ        
DK        
DE       1 trip; 1 000 trips 
IE        
ES        
FR        
IT        
CY        
LT        
NL        
AT        
PL        
PT        
SI        
SK More than 500 g More than 1 kg No definition No definition More than 100 pcs More than 100 pcs No definition 
FI        
SE        
UK        
HR        
TR        
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Table 6 — Methods used to collect wholesale drug prices 
  
Drug 
purchases Informants 
Interrogation 
of arrestees 
Wire-tapper 
registers and other 
covertly obtained 
audio material 
Market price 
appreciation 
from experts 
(police and 
academic) 
Documentation 
seized by law 
enforcement 
International 
cooperation 
Operational 
intelligence 
material 
Prosecution 
evidence 
papers/case 
files 
Social surveys 
and drug user 
counselling 
Academic 
surveys 
BE Seldom Frequently Frequently Seldom Seldom Frequently Seldom Frequently Never Never Seldom 
CZ Seldom Frequently Frequently Frequently Frequently Seldom Seldom Seldom Seldom Seldom Frequently 
DK Never Frequently Frequently Frequently Frequently Frequently - Frequently Frequently Never Never 
DE Frequently Frequently Frequently Frequently Frequently Frequently Frequently Frequently Never Never Never 
EE Seldom Frequently Frequently Seldom Frequently Frequently Seldom Seldom Frequently Seldom Seldom 
IE Seldom Seldom Seldom Never Never Seldom Seldom - Seldom Seldom Seldom 
ES Never Seldom Frequently Frequently Never Seldom Seldom Frequently Frequently Never Seldom 
FR Never Frequently Frequently Never Seldom Seldom Seldom Seldom Never Never Never 
IT Seldom Seldom Frequently Seldom Never Seldom Never Frequently Seldom Never Never 
CY Frequently Frequently Frequently Never Seldom Frequently Never Seldom Never Never Never 
LT Frequently Frequently Seldom Seldom - Never Seldom Seldom Never Never Never 
HU Never Seldom Frequently Seldom Seldom Seldom Never Seldom Never Never Seldom 
NL Never Frequently Frequently Frequently Frequently Frequently Frequently - Seldom Seldom Seldom 
AT Frequently Frequently Frequently Seldom Frequently Frequently Frequently Frequently Frequently Never Never 
PL Never Seldom Seldom Seldom Never Seldom Frequently Seldom Seldom Seldom Never 
PT Never Seldom Seldom Seldom Never Seldom Seldom Seldom Seldom Never Never 
RO Frequently Frequently Frequently Frequently Seldom Frequently Frequently Frequently Frequently Seldom Seldom 
SI Frequently Frequently Frequently Frequently Seldom Seldom Frequently Seldom Seldom Seldom Seldom 
FI 
- Frequently Frequently - Frequently Frequently - Frequently - - - 
SE Never Frequently Frequently Frequently Frequently Frequently Frequently Frequently Never Never Never 
UK Frequently Frequently Frequently Frequently Frequently Frequently Frequently Frequently Frequently Frequently Frequently 
HR Frequently Frequently Frequently Frequently Seldom Frequently Frequently Frequently Seldom Seldom Seldom 
TR Never Seldom Frequently Frequently Seldom Seldom Seldom Frequently - Seldom Never 
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Table 7.a — Statistical measures used to report wholesale drug prices 
 Cannabis resin Herbal cannabis Cocaine Heroin brown 
 
Min 
and 
Max Mean Mode Median Typical 
Min 
and 
Max Mean Mode Median Typical 
Min 
and 
Max Mean Mode Median Typical 
Min 
and 
Max Mean Mode Median Typical 
BE                                 
CZ                             
DK                                
DE                       
EE                       
IE - - - - - - - - - - - - - - - - - - - - 
ES                         
FR                       
IT                         
CY                     
LT                     
HU     -                
NL - - - - - - - - - - - - - - - - - - - - 
AT                         
PL                       
PT                       
RO                       
SI                             
SK                         
FI                           
SE                           
UK                       
HR                       
TR 
                              
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Table 7.b — Statistical measures used to report wholesale drug prices 
  Amphetamines Ecstasy LSD 
  
Min 
and 
Max Mean Mode Median Typical 
Min 
and 
Max Mean Mode Median Typical 
Min 
and 
Max Mean Mode Median Typical 
BE                         
CZ                      
DK                         
DE                
EE                
IE - - - - - - - - - - - - - - - 
ES                
FR                
IT                
CY               - 
LT           - - - - - 
HU                     
NL - - - - - - - - - - - - - - - 
AT                
PL                
PT                
RO                
SI                
SK                
FI                
SE                
UK                
HR                
TR                
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Table 8 — Reporting 
 
 
Regional wholesale  
drug prices Can you report them? 
Relate data to  
purity/potency data 
BE No Yes No 
CZ Yes No No 
DK Yes Yes No 
DE Yes No No 
EE No No Yes 
IE No No No 
ES No No Yes 
FR Yes Yes No 
IT Yes Yes No 
CY No No No 
LT No No No 
HU No No No 
NL Yes Yes No 
AT Yes No No 
PL No No Yes 
PT No No Yes 
RO No No Yes 
SI Yes Yes No 
SK Yes Yes Yes  
FI No No No 
SE No No No 
UK Yes Yes Yes 
TR Yes Yes Yes 
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Annex 3 — The main Questionnaire on wholesale drug prices 
 
 
frequent seldom never
Informants
Table 4.    Data collection  method
Drug purchases
Interrogation of arrestees
Debriefing convicted prisoners
Other covertly collected audio material
Documentation seized by law enforcement
International cooperation
Wire-tapper registers
Market price appreciation  from experts (police & academic)
Open source information (internet & public forums)
Academic and social surveys
Operational intelligence material
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Table 6. If you have applied a different methodology (to that requested by the questionnaire) please explain. 
Table 7. Provide detail of a particular trend or emerging market influence that has become apparent within the reporting period. 
Table 5. Please explain any changes in price collection methodology impacting upon the data submitted for this period.
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Annex 4 — The Sample questionnaire on wholesale drug prices 
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